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CHAPTER 1: INTRODUCTION 
1. CANCER AND TUMOR MICROENVIRONMENT  
Cancer remains one of the most important causes of death worldwide and accounted for 8.8 
million deaths globally in 2015 [1]. Briefly, cancer could be summarized as an uncontrolled 
growth of abnormal cells that are invasive, move to other sites in the body, and impair 
normal functioning of affected organs. Hanahan and Weinberg managed to comprehend this 
extremely complicated disorder by 10 hallmarks (Fig. 1).  
 
 
FIGURE 1: Hallmarks of cancer.  
The hallmarks of cancer constitute an organizing principle for rationalizing the complexities of 
neoplastic disease. These acquired capabilities of cancer include (1) sustaining proliferative signaling, 
(2) evading growth suppressors, (3) resisting cell death, (4) enabling replicative immortality, (5) 
inducing angiogenesis, and (6) activating invasion and metastasis. Conceptual progress in the last 
decades led to addition of 4 more hallmarks: (7) genome instability, which generates the genetic 
diversity that expedites their acquisition, (8) inflammation, which fosters multiple hallmark functions, 
(9) reprogramming of energy metabolism and (10) evading immune destruction, leading to a total of 
10 hallmarks. Adapted from [2]. 
 
Treatment of cancer has traditionally focused on eliminating cancer cells, by one, or a 
combination of the following treatments: surgery, chemotherapy and radiotherapy. Indeed, 
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tumors were formerly thought to be made of a nest of cancer cells only and research and 
therapies were focused only on the cancer cells (Fig. 2). At present, it is clear that the tumor 
microenvironment (TME) plays a crucial role in tumorigenesis. The TME consists of 
fibroblasts, immune cells and cells that comprise the blood vessels (pericytes, endothelial 
cells (EC’s)) and is believed to be the second building block of the tumor. These seemingly 
normal environmental cells actively enable the malignant progression through cell-cell 
interactions (cancer versus environment) [3]. 
 
FIGURE 2: Tumor micro-environment.  
The field of cancer research has largely been guided by a reductionist focus on cancer cells and the 
genes within them (above left). This view has evolved into a newer vision where tumors are seen as 
complex tissues in which mutant cancer cells have recruited seemingly normal cell types to act as 
active participants in their neoplastic development (beneath right). The interactions between the 
genetically altered malignant cells and the supporting microenvironmental cells are critical to 
understand cancer pathogenesis and to the development of novel, effective therapies. Adapted from 
[2, 3]. 
 
These important insights provided new approaches for cancer treatment that focused on the 
tumor as a whole (cancer cells + TME), like immunotherapy or anti-angiogenic therapy. An 
omnipresent feature of the TME is hypoxia. In the following sections, we describe the 
etiology of tumor hypoxia and highlight its importance as a potential target in cancer 
treatment, and as a predictive and prognostic biomarker.  
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2. TUMOR HYPOXIA 
A. ETIOLOGY 
Oxygen is a key factor in cell metabolism. It is extracted from air in the lungs, bound to 
hemoglobin in the blood and transported to the capillaries where it enters tissue cells 
through diffusion. The critical oxygen level required for normal cell functioning is 10 
mmHg [4]. Lower oxygen levels are considered hypoxic. In healthy tissues, oxygen delivery 
and consumption are well balanced, but tumors are prone to oxygen deficits for several 
reasons. First, consumption of oxygen is higher because cancer cells are highly 
proliferative. To meet this highly proliferative character, cancer cell’s energy metabolism 
is reprogrammed to aerobic glycolysis instead of oxidative phosphorylation, known as the 
Warburg effect [5]. Second, oxygen delivery is compromised due to the limited diffusion 
distance of oxygen (limited to about 150-200 µm). Some tumor cells are located too far 
from existing blood vessels leading to diffusion-limited hypoxia (Fig. 3) [6].  
 
FIGURE 3: Diffusion-limited 
hypoxia.  
Schematic illustration of oxygen 
diffusion from a capillary resulting 
in hypoxic cells. Oxygen diffuses 
an average of 150 µm from the 
capillary. Cells beyond this region 
are anoxic and nonviable. Cells at 
the periphery of this radius are 
hypoxic but viable. Adapted from [7]. 
 
Oxygen delivery is further compromised due to the dysfunctional tumor vasculature (Fig. 
4). This originates from the stimulation of tumor angiogenesis to cope with the fast growing 
tumor cells (one of the hallmarks of cancer [2]). Instead of forming well-structured 
functional vessels, tumor vessels are dilated, tortuous and the vessel wall is more permeable. 
These immature vessels eventually lead to a hypoxic and acidotic tumor microenvironment 




FIGURE 4: Tumor angiogenesis.  
(Left) Normal vasculature. There is a balance between progrowth and antigrowth factor signals 
leading to an organized network, with large vessels regularly branching into smaller ones. (Right) 
Abnormal tumor vessels. There is an excessive number of proangiogenic factors, primarily vascular 
endothelial growth factor (VEGF), which causes an overgrowth of disorganized vessels that are 
typically permeable, dilated and tortuous. Adapted from [8]. 
 
Depending on the duration of hypoxia, two main types have been distinguished: chronic 
and cycling hypoxia, initially called acute hypoxia [9]. Chronic hypoxia is characterized by 
a deficit in O2 for a continuous period in time (at least several hours). This is believed to 
originate mostly from diffusion-limited hypoxia and the immature tumor vasculature. 
Cycling hypoxia, on the other hand, describes a hypoxia-reoxygenation pattern in which 
periods of poor and better perfusion alternate. It is believed to originate from perfusion-
limited hypoxia where an intermittent constriction of tumor blood vessels lead to 
interruptions in tumor perfusion (Fig. 5).  
 
FIGURE 5: Cycling hypoxia.  
Immunofluorescence staining of a mouse tumor 
section depicting endothelial cells (red, CD31-
staining), perfused vessels (blue, Hoechst 33342 
injected 2 min before mouse sacrifice) and hypoxia 
area (green, pimonidazole staining). Note the 
existence of endothelial cells (red) in the hypoxic 
regions (green), reflecting ongoing angiogenesis or 
non-perfused blood vessels. Adapted from [9]. 
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All these factors contribute to tumor hypoxia, which is distributed heterogeneously between 
tumor types, between individuals, and within the same tumor (space/time) and is present in 
up to 60% of locally advanced solid tumors [6, 10].  
 
B. TUMOR RESPONSE TO HYPOXIA 
One could think that hypoxia leads to starvation of the tumor resulting in growth arrest, cell 
death and tumor growth inhibition, but the opposite occurs. Three main oxygen sensitive 
signaling pathways are activated independently where the Hypoxia Inducible Factor- 1 
(HIF- 1) pathway is the most important one (Fig. 6). The Mammalian (or Mechanistic) 
Target Of Rapamycin (mTOR) and the Unfolded Protein Response (UPR) pathways are 
also activated. Through different intermediate steps, they lead to changes in cell metabolism 
and functioning and eventually result in adaptation and resistance of the cancer cells to 
hypoxia [6, 11-13]. 
 
 
FIGURE 6: Cellular response to hypoxia.  
(1) Hypoxia stabilizes hypoxia-inducible factor 1α (HIF- 1α), facilitating heterodimerization with 
HIF- 1β and transcriptional activation of many genes. (2) Hypoxia triggers the unfolded protein 
response (UPR) by activation of the endoplasmic reticulum (ER) stress sensors PKR-like ER kinase 
(PERK), inositol-requiring protein 1 (IRE1) and, most probably, activating transcription factor 6 
(ATF6). IRE1 and ATF6 both contribute to a transcriptional response whereas PERK causes 
inhibition of mRNA translation. (3) The activity of mTORC1, a complex containing the mammalian 
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target of rapamycin (mTOR) kinase, which integrates and transmits positive and negative growth 
signals to the translational machinery, is inhibited by hypoxia. Together these three pathways 
influence the phenotype of hypoxic cells by altering metabolism, angiogenesis, autophagy and ER 
homeostasis. Adapted from [12]. 
 
Tumor cells do not only succeed in adapting their cell metabolism to the hypoxic 
circumstances, they also evolve to a more aggressive phenotype. It has been shown that 
tumor hypoxia is correlated with sustained angiogenesis [14], metastasis and invasion [15, 
16], escaping apoptosis [17], suppression of the immune response [18] and genomic 
instability [19, 20], all hallmarks of cancer [2].  
Further, clear associations with radio- and chemoresistance have been described [21-23]. 
The underlying mechanism of radioresistance is based on the crucial role of oxygen in the 
radiochemical process to cause DNA damage. Oxygen facilitates the making of DNA strand 
breaks by free radicals, as a result of ionizing radiation. In the absence of oxygen, 2-3 times 
higher doses of irradiation are needed to cause the same amount of DNA damage, also called 
the oxygen enhancement ratio (OER) and illustrated in Figure 7.  
 
FIGURE 7: Schematic representation 
of the relationship between 
radiosensitivity and oxygen tension.  
This graph summarizes the results of in 
vitro experiments with EMT6 mouse 
mammary tumor cells. Briefly, these were 
irradiated at different oxygen tensions 
with 250 kV x-rays. Cell survival was 
measured immediately after irradiation 
using a colony formation assay. 
Importantly this illustrates that the 
radiosensitivity increases rapidly as the oxygen tension rises from anoxia to ∼10 Torr. At higher 
concentrations of O2, similar to those found in venous blood, the radiosensitivity plateaus and does 
not increase greatly as the oxygen tension rises to that of cells equilibrated with air or with 100% O2 
at normal atmospheric pressure or even hyperbaric pressures (HBO). Adapted from [24, 25]. 
 
Tumor hypoxia was proven to be an independent negative predictive and prognostic factor 




TABLE 1: Representative examples of the prognostic and predictive significance of hypoxia in 
human cancer.  
CA9= carbonic anhydrase 9= endogenous hypoxia marker; CHART= continuous hyperfractionated 
accelerated radiotherapy; DFS= disease free survival; EF5= etanidazole pentafluoride; HIF= hypoxia-
inducible factor; HNSCC= head and neck squamous cell carcinoma; OS= overall survival. PSA= 
prostate specific antigen. Adapted from [26]. 
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In conclusion, hypoxia is present to some extent in all solid tumors and has been correlated 
with treatment resistance and patients’ prognosis. This makes it on the one hand an 
attractive target for therapy modifications and improvements, and on the other hand, an 
interesting biomarker to predict treatment response (predictive biomarker) and survival 
(prognostic biomarker). 
 
3. TARGETING TUMOR HYPOXIA 
The importance of hypoxia in solid tumors has been recognized and investigated for over 
100 years. Hereby, a diversity of therapies have been developed to act on this 
microenvironmental phenomenon. In this section we summarize some major mechanisms 
in targeting hypoxia. 
 
A. ENHANCING OXYGEN DELIVERY 
Therapies to enhance the oxygen delivery by the blood were developed in the idea it would 
make tumors less radioresistant. Older studies tested the effect of blood transfusions and 
administration of erythropoietin (EPO) to increase hemoglobin levels and oxygen transport, 
but had questionable results as it was shown that EPO also increases tumor cell proliferation 
[27]. Later, different breathing schedules were tested like hyperbaric oxygen (HBO) or 
carbogen, a hyperoxic gas (95%- 98% O2 and 2%- 5% CO2) [28]. Combination with 
nicotinamide, a vitamin B3 analog and vasoactive agent, and accelerated radiotherapy led 
to the ARCON strategy, accelerated radiotherapy with carbogen and nicotinamide. It would 
counteract cellular repopulation and reduce diffusion- and perfusion-limited hypoxia. 
ARCON seems the most promising with good local control rates in head and neck and 
bladder cancers in phase II trials [29].  
 
However, the two main approaches to target hypoxia in cancer are the use of bioreductive 
prodrugs on the one hand, and drugs that inhibit molecular targets upon which hypoxic cell 
survival depends on the other hand [26]. 
 
B. BIOREDUCTIVE PRODRUGS 
The bioreductive prodrugs, also called hypoxia activated prodrugs (HAP’s), are 
administered in their inactive state and are activated in hypoxic cells ensuring hypoxia 
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specific functioning [26]. Five groups of chemical structures have been identified with these 
hypoxia specific activation properties: nitro groups, aromatic N-oxides, aliphatic N-oxides, 
quinones and transition metals [30]. Figure 8 illustrates the chemical mechanism underlying 
the hypoxia dependent activation of HAP’s with a nitro group, also called oxygen dependent 
redox cycling.  
 
 
FIGURE 8: Mechanism of hypoxia dependent activation of HAP’s with a nitro group.  
The prodrug has entered the cell through diffusion and is reduced enzymatically by intracellular 
reductases. Under normoxic conditions, oxygen takes back the electron, reversing the reduction and 
returning the drug to its inactive state. Under hypoxic conditions, the reduction activates the prodrug 
to its active state of a radical anion. Adapted from [31]. 
 
The nitroimidazoles have besides the hypoxia specific cytotoxic activity also a hypoxic 
radiosensitizing effect. They are able to replace the effect of oxygen in the radiobiological 
process, in producing free radicals and generating cytotoxic DNA strand breaks. The 
oxygen enhancement ratio is valued at 1.5 to 2 maximally, thereby not reaching the level of 
normoxic conditions [32]. Misonidazole was the first tested nitroimidazole combined with 
radiotherapy. Several randomized clinical trials were performed, which proved the proof of 
principal, but due to high toxicities (neuropathy) and lack of major benefits on clinical 
outcomes, this was not adopted in daily clinic [33, 34]. Nimorazole however (Fig. 9), 
showed to improve clinical outcomes in head and neck cancer and is now used in daily 
practice in Denmark [35]. It is a 5-nitroimidazole with lower cytotoxicity and neurotoxicity. 














C. TARGETING THE HYPOXIC CELL  
The use of drugs that inhibit molecular targets upon which hypoxic cell survival depends, 
mainly concern the three primary hypoxia-sensing signaling pathways HIF, UPR and 
mTOR [26]. Different drugs have been developed that interfere with HIF1α expression, 
HIF1 transcription, HIF1 target gene products (CA9, Glut1), receptor tyrosine kinases 
(VEGFR, EGFR), RAS-MAPK signaling, mTOR (autophagy, mTORC1) and UPR 
(SERCA, HSP90). Different examples of HIF-targeted therapies are summarized in Table 
2. 
 
Currently, no clear clinical evidence exists yet of antitumor activity due to direct HIF1 
inhibition, UPR targeting is still in the in vitro phase and also mTOR inhibitors (e.g. 
rapamycin) area still in their preclinical phase. Targets downstream the primary hypoxia-
sensing pathways are also investigated, like inhibiting autophagy (induced by UPR), 
inhibiting glycolysis (induced by HIF1 and mTOR), and targeting DNA damage response 
and repair pathways in response to hypoxia are investigated, like reactivating p53 to restore 
hypoxia-mediated apoptosis. These newer approaches are just at their start.  
Targeting hypoxia induced angiogenesis on the other hand, has been studied extensively 








TABLE 2: Inhibitors of HIF activity by different mechanisms and targets. Adapted from [36]. 
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- VEGF(R) INHIBITION 
In response to hypoxia, vascular endothelial growth factor (VEGF) is secreted by cancer 
cells and cancer associated stromal cells (EC, CAF’s, macrophages). VEGF binds its 
receptor (VEGFR), mainly located on endothelial cells (EC) of blood vessels and lymphatic 
vessels, and induces angiogenesis by promoting survival, proliferation and migration of EC, 
increasing the display of adhesion molecules and increasing vascular permeability [37]. It 
is one of the major driving forces of survival of hypoxic cancer cells. Anti-angiogenic 
therapy through inhibition of VEGF(R) blocks these pathways. Depending on the resulting 
balance between pro- and anti-angiogenic factors, inhibition of VEGF(R) induces a 
normalization of the tumor vasculature (leading to better delivery of nutrients, oxygen 
(radiosensitizer) and drugs (chemo- or immunotherapy)), or the inhibition induces a 
regression of tumor vasculature (leading to tumor ‘starvation’ [38], but also an increase in 
hypoxia and a more hostile TME). With the eye on targeting hypoxia, normalization is 
aimed at. Radio-, chemo- and immunotherapy efficiency depend on tumor perfusion and 
oxygenation. Theoretically, combination with VEGF(R) inhibition could have synergistic 
effects and indeed this synergism has been proven for the combination with chemotherapy. 
Bevacizumab (Avastin®), for example, a VEGFA antibody, has been FDA-approved 
((BLA) 125085) for treatment of different cancer types such as first line treatment of 
metastasized colorectal cancer in combination with chemotherapy [39]. Timing and dosage 
of VEGF(R) inhibition is important as is explained in figure 10 [40, 41].  
 
FIGURE 10: Normalization window.  
Proposed effect of drug dose and schedule on 
tumor vascular normalization. The efficacy of 
cancer therapies that combine antiangiogenic and 
cytotoxic drugs depends on the dose and delivery 
schedule of each drug. The vascular normalization 
model posits that a well-designed strategy should 
passively prune away immature, dysfunctional 
vessels and actively fortify those remaining, while 
incurring minimal damage to normal tissue 
vasculature. During this “normalization” window 
(green), cancer cells may be more vulnerable to 
traditional cytotoxic therapies and to novel 
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targeted therapies. The degree of normalization will be spatially and temporally dependent in a tumor. 
Vascular normalization will occur only in regions of the tumor where the imbalance of pro- and 
antiangiogenic molecules has been corrected. Adapted from [41]. 
 
In conclusion, numerous therapies exist to target hypoxia and improve treatment outcomes. 
Most of them showed promising results in the early trials, but eventually failed to confirm 
their benefit in phase III trials. For sure, this has to do with the lack of patient selection. The 
key to prove success of hypoxia modification lies in adequate patient selection. Therefore, 
methods to detect and quantify tumor hypoxia are needed and are discussed in the following 
section. 
 
4. DETECTING TUMOR HYPOXIA [42-44] 
 
A. pO2 PROBE MEASUREMENTS 
Direct measurement of pO2 with a polarographic needle electrode system (pO2 histograph, 
Eppendorf, Hamburg, Germany) inserted in different tracks in the tumor, has long been the 
golden standard [45] (Table 3). This technique is based on the polarographic reduction of 
molecular oxygen at a cathode sensor, covered by a semipermeable membrane, inducing a 
current [46]. The magnitude of this current is linearly correlated with the amount of oxygen 
at the cathode and thus with the partial oxygen tension. In the clinical setting, it could 
confirm the hypothesis that hypoxia is a negative prognostic marker in different tumors (e.g. 
cervix cancer, soft tissue sarcomas, head and neck cancer) [47-49]. Later, the fluorescence-
based fiberoptic probe followed (OxyLite, Oxford Optronix, UK) [50]. Short pulses of LED 
light are transmitted along the fiberoptic sensor and excite a platinum-based fluorophore at 
the sensor tip. The resulting emission of fluorescent light, quenched by the presence of 
oxygen molecules, is detected and the lifetime of fluorescence is inversely proportional to 
the concentration of dissolved oxygen.  
 
These pO2 probe systems proved their use, but major disadvantages remain, like their 
invasiveness, operator dependency, sample size dependency and most importantly their 
inapplicability for deeper lying pathologies and repetition of measurements. At present, they 




pO2 probe system Advantage Disadvantage 
Polarographic 
needle 
- rapid data sampling - oxygen consumption 
during read-out 
- not reaching a steady state 
Fluorescence-based 
fiberoptic needle 
- measuring at individual 
locations over a 
prolonged period 
- absence of oxygen 
consumption 
- stabilization period of 1-2 
min before measuring 
 
TABLE 3: Comparison of polarographic and fluorescence-based pO2 probe systems. 
 
B. IMMUNOHISTOCHEMISTRY 
Immunohistochemical detection of hypoxia is another frequently used quantification 
method. Endogenous hypoxia markers (e.g. HIF-1α or CA9) or exogenous markers that are 
administered before biopsy (e.g. pimonidazole or EF5 (2-(2-Nitro-1H-imidazol-1-yl)-N-
(2,2,3,3,3-pentafluoropropyl) acetamide)), are stained in tumor specimens [51] (Fig. 11). 
This technique however implies taken biopsies, is sample size dependent, difficult for 
deeper lying structures, difficult to repeat and difficult to quantify.  
 
 
FIGURE 11: Immunohistochemistry to detect hypoxia.  
SQ20b subcutaneous tumor in hind leg of nude mice. (A) H&E staining of tumor section. (B) 
Immunofluorescent pimonidazole staining of consecutive section (green). Pimonidazole was 
administered intravenously 90 min before sacrifice. The tumor was perforated with a 28-gauge 
angiocatheter after resection to facilitate tumor section orientation after staining (circular defect in the 




Autoradiography is the technique of recording an image of a preparation that contains 
radioactivity using a radiation-sensitive medium. The radioactive samples are placed 
directly against a film for a period to allow radioactive emissions from the sample to interact 
with the film emulsion and this creates an image (Fig. 12).  When using a hypoxia tracer, 
the image represents hypoxic areas. This technique is mostly used for biodistribution studies 
or validity studies in tracer development, but is less suited for predictive and prognostic use 




FIGURE 12: Distribution of 18F-FAZA with autoradiography versus immunofluorescent 
staining.  
SQ20b murine xenografts. Registered 3-color immunofluorescent image (A) and corresponding 
autoradiography (B) from tumor section. Blue= Hoechst (perfusion marker); green= pimonidazole 
(hypoxia marker); red= CA9 (hypoxia marker); yellow= overlay of pimonidazole and CA9.  (C) 
Rebinned scatterplots showing relationship between fluorescence markers on y-axis, and indicated 
hypoxia radiotracer on x-axis. Areas of hypoxia on immunofluorescent staining correspond with areas 
of high 18F-FAZA activity on autoradiography. Adapted from [52]. 
 
28 
D. GENETIC MARKERS 
Intense efforts have been made to identify a gene signature correlating with tumor hypoxia 
and having predictive and prognostic capacities. To date, 32 hypoxia gene expression 
signatures have been published and are summarized in a recent review [53]. An ongoing 
RCT investigates whether nimorazole with cisplatin-based CRT in patients with locally 
advanced head and neck cancer is superior to CRT alone, using a 15-gene hypoxia signature 
(ClinicalTrials.gov:NCT01880359). At our center, blood samples of esophageal cancer 
patients (pre, during and post treatment) are being collected in a biobank with the eye on 
identifying a predictive and prognostic gene signature. 
 
E. IMAGING METHODS 
Besides genetic biomarkers, imaging modalities are another very interesting non-invasive 
method to detect hypoxia and are summarized in Table 4 [44, 54, 55]. 
 
Optical based methods are being used like phosphorescence or near-infrared spectroscopy 
(NIRS) [44]. These calculate the hemoglobin oxygen saturation (StO2) by measuring 
phosphorescence (oxygen dependently quenched) or optical absorption (different for oxy- 
and deoxyhemoglobin) (Fig. 13). Hyperspectral imaging (HSI), a third optical based 
imaging method, determines the electromagnetic spectrum of each pixel of an image [56]. 
As such, it can provide a very detailed image map of the hemoglobin saturation at the 
microvascular level. The major limitation of these optical based techniques is that they 
measure intravascular pO2 instead of tissue pO2 as a parameter for hypoxia.  
 
FIGURE 13: Absorption spectra of oxy- and 
deoxyhemoglobin.  
The absorption spectra of oxygenated and 
deoxygenated hemoglobin differ. For example, 
at a wavelength of 660 nm (red light), 
deoxygenated hemoglobin absorbs more light 
than oxygenated hemoglobin. The opposite 
occurs at a wavelength of 940 nm (infrared 
light), where oxygenated hemoglobin absorbs 
more light than deoxygenated hemoglobin. By measuring the absorption at different wavelengths, the 





TABLE 4: Examples of non-invasive methods for hypoxia determination in living tissues. 






Further, magnetic resonance imaging (MRI) based modalities are being used like blood 
oxygen level-dependent (BOLD-) MRI, electron paramagnetic resonance imaging (EPRI) 
or dynamic contrast enhanced (DCE-) MRI [58]. These have low specificity for tissue 
hypoxia because they actually measure perfusion and vascular oxygenation.  
 
Finally and most importantly, nuclear imaging is being used which offers several 
advantages compared to the previously mentioned methods. It measures tissue hypoxia and 
not vascular oxygenation, the hypoxia distribution is imaged in a 3-dimensional way (3D), 
the imaging can be repeated allowing the evaluation of changes in hypoxia status, and whole 
tumor quantification is possible [59, 60]. A hypoxia specific tracer coupled to a radionuclide 
is injected and imaged with positron emission tomography (PET) or single-photon emission 
computed tomography (SPECT), according to the injected radionuclide. A good hypoxia 
tracer should be highly specific for hypoxia (oxygen-specific retention mechanism), have a 
fast uptake and homogeneous distribution in tissues, and thus be lipophilic to diffuse 
through the cell membrane, but at the same time have a fast washout from non-hypoxic 
tissue with fast elimination, and thus be hydrophilic [61, 62]. No tracer meets all criteria, 
but the family of nitroimidazoles showed the most promising results (Table 5).  
 
Hypoxia specific tracer entrapment of nitroimidazoles is based on sequential reduction 
reactions of the NO2-group under hypoxic conditions and eventually binding to intracellular 
macromolecules [31]. 18F-FMISO (fluoromisonidazole) was the first to be developed and 
provided the broadest evidence as a hypoxia tracer (Table 5). Due to its lipophilic character, 
clearance from non-hypoxic tissues is slow and tumor-to-background contrast is not optimal 
[61]. Development of several second generation tracers followed, with slightly adapted 
pharmacokinetic properties to improve tumor-to-background contrast (Table 5). 18F-FAZA 
(fluoroazomycin arabinoside), for example, was developed as an adaptation of FMISO in 
which the alkyl side chain of FMISO was replaced by a polar arabinose sugar (Fig. 14) [63]. 
This increased the hydrophilicity of the molecule, leading to an increased clearance from 







TABLE 5: Nitroimidazole hypoxia tracers for PET imaging. Adapted from [54] and extended with 




FIGURE 14: Molecular structure of 18F-FMISO and 18F-FAZA. 
 
 
18F-HX4 (flortanidazole) [73], 18F-FETNIM (fluoroerythronitroimidazole) [74] and 18F-
EF5 (2-nitroimidazol-pentafluoropropyl acetamide  [75] are other examples of second 
generation nitroimidazole tracers that were developed to overcome the limitations of 
FMISO. Main studies, benefits and limitations are summarized in Table 5.  
In the end, nitroimidazole-based PET tracers have proven reliability in measuring tumor 
hypoxia, with each tracer having its advantages and disadvantages, but overall only modest 
differences. This thesis focused on 18F-FAZA for several reasons. 18F-FAZA is a feasible 
tracer to detect tumor hypoxia and has indeed superior biokinetics compared to 18F-FMISO 
[76, 77]. 18F-FAZA PET was studied in different tumors and showed to be predictive for 
treatment response in rhabdomyosarcoma and breast carcinoma (preclinical) [78, 79], and 
NSCLC and HNSCC (clinical) [80, 81]. Further, clinical trials are ongoing for rectal, lung, 
cervix and prostate carcinoma (ClinicalTrials.gov: NCT02624115, NCT02701699, 


























CHAPTER 2: OBJECTIVES AND THESIS OUTLINE 
Despite ongoing progression in oncology, there is a lack of patient-specific approaches 
based on biomarkers. The objective of this thesis was to use tumor hypoxia, an omnipresent 
feature of the TME, as a biomarker and target for treatment in solid tumors.  
 
Two main research questions were investigated: 
1. Can hypoxia imaging with 18F-FAZA PET/CT serve as a predictive biomarker and as a 
guidance for hypoxia targeting? 
2. Can anti-angiogenic therapy reduce hypoxia by vascular normalization and enhance 
radiotherapy efficacy? 
 
The first question was studied in an esophageal adenocarcinoma tumor model. Most patients 
with esophageal adenocarcinoma are diagnosed in a locally advanced stage and are 
standardly treated with neoadjuvant chemoradiotherapy followed by surgery. This 
treatment is associated with a considerable morbidity and treatment response is highly 
variable and unpredictable, making it an interesting pathology for a patient-tailored 
approach based on biomarkers [82]. Further, evidence exists (mostly histologically) that 
tumor hypoxia plays a role in treatment resistance in esophageal cancer [83, 84].  
 
Because no appropriate tumor model was available for our research objective, our first aim 
was to develop an EAC model in mice, which is described in chapter 3. 
 
Subsequently, we aimed to evaluate the feasibility of 18F-FAZA PET/CT in the orthotopic 
and subcutaneous EAC model which is outlined in chapter 4.  
 
Finally, we aimed to use 18F-FAZA PET/CT as hypoxia detection method to predict 
radiation response in our tumor model. In chapter 5 we describe the predictive value of 
18F-FAZA PET/CT in EAC xenografts for radiation response. We further evaluated if 18F-
FAZA PET/CT could identify tumors that might benefit from hypoxia targeted therapy to 
improve radiation response. To target hypoxia, we used nimorazole, a 5-nitroimidazole that 
mimics oxygen in the radiobiological process and has already showed to successfully 




The second research question, regarding the effect of anti-angiogenic therapy on hypoxia 
and radiotherapy, was discussed in chapter 6 in a colorectal cancer tumor model. This 
model was chosen because CRC tumors are highly angiogenic and were one of the first 
tumor types that showed significant response to anti-angiogenic therapy. We were 
interested in the effects of anti-angiogenic agents on hypoxia and radiotherapy efficacy. 
This could be of special interest for patients with locally advanced rectal cancer (LARC), 
who receive chemoradiation before surgical resection. Anti-angiogenic agents might 
enhance pathological response and outcomes. We aimed to link tumor hypoxia with tumor 
angiogenesis and aimed to target it by administration of a pan-VEGFR inhibitor cediranib. 
We evaluated tumor hypoxia with a fluorescence based fiberoptic oxygen probe (Oxylite) 
and with immunohistochemistry (endogenous marker pimonidazole). The underlying 
structural and functional vascular changes were investigated by in vivo imaging in dorsal 


























CHAPTER 3: ESOPHAGEAL ADENOCARCINOMA 




 This chapter is based on the following article: 
Melsens E, De Vlieghere E, Descamps B, Vanhove C, De Wever O, Ceelen W, 
Pattyn P. Improved xenograft efficiency of esophageal adenocarcinoma cell lines 
through in vivo selection. Oncol Rep, 38: 71-81, 2017.  
 
ABSTRACT 
Background: Esophageal adenocarcinoma is an aggressive disease with rising incidence 
rates. The need for development of new therapies is high and preclinical research plays 
herein a crucial role. However, there is a lack of preclinical (orthotopic) EAC models. We 
aimed to develop an EAC model in mice.  
Methods: Two esophageal adenocarcinoma cell lines, OE33 and OACM5 1.C, and a third 
in vivo selected subpopulation, OACM5 1.C SC1, were used. One group of mice was 
injected subcutaneously in the hind legs. Tumor growth was followed with calipers. 
Another group was injected orthotopically in the distal esophageal wall through median 
laparotomy. Tumor development was evaluated macroscopically and confirmed 
microscopically and tumor take rates were calculated. A subset of mice was evaluated with 
MRI to follow tumor progression. Additionally, functional cell line characteristics were 
evaluated in vitro (clonogenic assays, collagen invasion assays, sphere formation assays 
and protein analysis of cell-cell adhesion and cytoskeletal proteins) to better understand 
xenograft behavior.  
To answer our first research question ‘Can hypoxia imaging with 18F-FAZA 
PET/CT serve as a predictive biomarker and as a guidance for hypoxia 
targeting?’, we first developed an esophageal adenocarcinoma model in 
mice, which is described in this chapter. 
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Results: OE33 cells were shown to be epithelial-like, whereas OACM5 1.C and OACM5 
1.C SC1 were more mesenchymal-like. The three cell lines were non-invasive into native 
type I collagen gels. In vivo, OE33 cells led to 63.6% and 100% tumor nodules after 
orthotopic (n= 12) and subcutaneous (n= 8) injection, respectively. Adversely, OACM5 1.C 
cells did not lead to tumor formation after orthotopic injection (n= 6) and only 50% of 
subcutaneous injections led to tumor nodules (n= 8). However, the newly established cell 
line OACM5 1.C SC1 resulted in 33% tumor formation when injected orthotopically (n= 6) 
and in 100% tumors when injected subcutaneously (n= 8). The higher xenograft rate of 
OACM5 1.C SC1 (P< 0.05) corresponded with a higher clonogenic potential compared to 
its parental (P< 0.0001). All models showed local tumor growth without metastasis 
formation.  
Conclusion: In conclusion, OACM5 1.C has a poor tumor take rate at an orthotopic and 
ectopic site. A subpopulation obtained through in vivo selection, OACM5 1.C SC1, gives a 
significant higher take rate ectopically. Further, OE33 establishes orthotopic (and 
subcutaneous) xenografts in mice. Our paper provides an orthotopic and subcutaneous 
xenograft EAC model in mice, which will hopefully contribute to further preclinical 




Esophageal cancer is the eighth most frequent cancer worldwide [85]. Despite the latest 
evolutions in treatment, overall mortality of esophageal cancer patients remains high, with 
a 5-year survival of only 9.8% in Europe [86, 87]. Therefore, the need for development of 
new therapies is high and preclinical research plays herein a crucial role.  
The majority of preclinical research in esophageal carcinoma has been performed in 
heterotopic models (subcutaneous xenograft tumors) [88]. However, orthotopic tumor 
models, where tumors are grown at their primary site, are preferred, because they resemble 
tumor development in patients more closely [89]. Furthermore, it has been proven that 
interaction between the tumor and its microenvironment plays a crucial role during 
carcinogenesis [2]. This tumor microenvironment is considerably different when 
esophageal tumors are grown subcutaneous (heterotopic), i.e. different blood supplies 
leading to different metastatic routes.  
Some preclinical research in esophageal carcinoma has been performed on orthotopic 
models. Tumor cells were injected either directly in the esophageal wall, or subcutaneously 
in donor animals to transplant tumor fragments onto the surgically injured esophageal wall. 
The surgical procedures to induce orthotopic esophageal tumors are technically challenging 
due to the location and size of the esophagus in laboratory animals (mostly mice). Five 
surgical approaches to the esophagus have been described: (i) median laparotomy [90-95], 
(ii) median laparotomy combined with transgastric approach [96], (iii) subcostal laparotomy 
[97], (iv) transoral approach [98], and (v) cervical approach [99]. Tumor take varied 
between 0% and 100% (mean 80.06%) and seemed to depend more on the aggressiveness 
of the tumor cell line, than on the surgical technique. A total of 9 different esophageal 
squamous cell carcinoma (ESSC) cell lines (81-T, KYSE30, KYSE150, SLMT-1, TE1, 
TE8, TE4, TE10 and T.Tn) and 3 esophageal adenocarcinoma (EAC) cell lines (OE19 [92, 
94, 100, 101], PT1590 [93, 102] and OE33 [92]) were described for orthotopic use. Because 
EAC has become the main subtype in patients in the United States and Northern and 
Western Europe [103], this study will focus on EAC. Overall, there is a lack of preclinical 
orthotopic EAC models. Of the 3 EAC cell lines previously described for orthotopic use, 
OE33 represents locally advanced EAC. This cell line was used by Habibollahi et al. for 
diagnostic properties [92], but only in 5 mice. They described orthotopic OE33 tumors of 
2-3mm in diameter at 4 weeks after injection. OE19 and PT1590 on the other hand, are 
representative cell lines for aggressive metastatic EAC. Moreover, OE19 overexpresses 
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Her2, which is found in only a minority of EAC patients (17- 32% of gastro-esophageal 
junction tumors GEJ [104]). 
The purpose of this study was to establish an orthotopic EAC model in the mouse based on 
two generally available human EAC cell lines, OE33 and OACM5 1.C. In vivo tumor take 
and growth were evaluated (orthotopic as well as subcutaneous) and in vitro cell line 
characterization was performed. 
 
MATERIALS AND METHODS 
IN VITRO 
CELL LINES 
The human EAC cell lines OE33 and OACM5 1.C were obtained from Dr. W. Dinjens, 
Department of Pathology, Erasmus MC, Rotterdam, the Netherlands, and are available at 
the European Collection of Authenticated Cell Cultures (ECACC), number 96070808 and 
11012006 respectively. MDA-MB-231 GFP Luc, human mammary carcinoma cell line 
(ATCC: HTB-26), and HCT8/E11, human colon adenocarcinoma cell line (ATCC number: 
CCL-244), were controls for in vitro experiments. OE33, HCT-8/E11 and MDA-MB-231 
GFP Luc were cultured at 37 °C in 10% CO2 humidified atmosphere in DMEM medium 
(Life Technologies, Ghent, Belgium), supplemented with 10% fetal bovine serum, 
penicillin-streptomycin and fungizone. Doxycycline (50 µg/ 100 ml medium) was added to 
the medium of MDA-MB-231 GFP Luc to express GFP. OACM5 1.C and the in vivo 
selected cell line OACM5 1.C SC1 (see further) were cultured at 37 °C in 5% CO2 
humidified atmosphere in RPMI 1640 Medium (Life Technologies) supplemented with 
GlutaMAX™-I (Life Technologies), 10% fetal bovine serum, penicillin-streptomycin and 
fungizone. EAC cell lines and the in vivo selected cell line OACM5 1.C SC1 were 
authenticated by STR DNA profiling. Microscopic images were taken with a phase contrast 
microscope (Leica DMI3000B, Diegem, Belgium). 
 
SPHERE FORMATION ASSAY 
One million single cells were diluted in 6 ml culture medium in an Erlenmeyer flask (50 
ml). They were incubated for 72 hours on a Gyrotory shaker at 37 °C and 70 rpm in 5 or 
10% CO2. Aggregation was analyzed with a phase contrast microscope and was scored on 
at least 50 aggregates. They were scored as compacted (individual cells not visible) or loose 
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(individual cells still visible) (n= 2). HCT8/E11 and MDA-MB-231 GFP Luc were used as 
a control for a respectively compacted and loose sphere formation. 
 
COLLAGEN INVASION ASSAY 
The assay was performed according to De Wever et al. [105]. Briefly, 1x105 cells were 
seeded as a single cell suspension on a 0.1% type I collagen gel (Santa Cruz). After 24 h 
incubation at 37 °C and 5 or 10% CO2, invasiveness was scored (n= 2x2) and expressed as 
a mean. HCT8/E11 and MDA-MB-231 GFP Luc were used as a control for a respectively 
low and high invasive cell line. 
 
COLONY FORMATION ASSAY 
1000 single cells were seeded in T75 falcons (15 ml culture medium) and cultured for 14 
days at 37 °C. Colonies were stained with 0.5% crystal violet, scanned and counted using 
ImageJ software (NIH). Results were expressed as the mean percentage of colonies formed 
out of 1000 cells (colony formation index (CFI)) (n= 2x5). HCT8/E11 and MDA-MB-231 




Cells were lysed and sonicated for 10 seconds on ice. Lysates were diluted to a protein 
concentration of 1 µg/ µl and boiled for 5 minutes at 95 °C. Equal amounts of proteins were 
separated on 8 and 10% gels and transferred to nitrocellulose membranes. Membranes were 
blocked (PBS, 5% non-fat milk, 0.5% Tween) and immunostained with primary antibodies: 
E-cadherin M106 (TaKaRa, The Netherlands), P-cadherin 610228 (BD Biosciences, 
Belgium), vimentin V6389, α-catenin C2081, β-catenin C2206, and cytokeratin C2931, 
recognizing subtype (4, 5, 6, 8, 10, 13 and 18), (Sigma-Aldrich, St. Louis, MO, USA). Then, 
secondary antibodies were applied, either ECLTM Anti-Mouse IgG or ECLTM Anti-Rabbit 
IgG (GE Healthcare UK Limited, UK). Immunodetection was performed with Pierce ECL 
Western Blotting Substrate (Thermo Scientific, Rockford, IL, USA) and imaged with 
Proxima2850 (Isogen, Life Science, Belgium). HCT8/E11 was used as positive control for 
E-, P-cadherin and cytokeratin. MDA-MB-231 GFP Luc was used as a positive control for 






Animal experiments were approved by the Animal Ethical Committee of Ghent University, 
Belgium (ECD 14/82). Athymic mice (Foxn1nu male) were obtained from Envigo, the 
Netherlands, and were kept under environmentally controlled conditions (12 h normal light/ 
dark cycle, 20- 23 °C and 50% relative humidity) with food and water ad libitum. At 8 
weeks of age, tumor cells were implanted (subcutaneous or orthotopic) under general 
anesthesia (Isoflurane, Abbott, Belgium). At the end of the experiments, or when humane 
endpoints were reached, mice were euthanized by cervical dislocation.  
 
SUBCUTANEOUS TUMOR MODEL 
Subcutaneous tumors were grown to evaluate overall growth behavior of the cell lines in 
mice and to provide tumors for in vivo selection of cancer cells. Under general anesthesia, 
tumor cells suspended in 100 µl of Matrigel/injection site were injected SC in both hind 
legs. Tumor nodules were measured biweekly with calipers and volumes were calculated 
according to the following formula: 𝑉 = (𝑙𝑒𝑛𝑔𝑡ℎ × 𝑤𝑖𝑑𝑡ℎ)3/2 × 𝜋/6.  
 
ORTHOTOPIC TUMOR MODEL 
Mice were positioned supine on a heating pad. Under general anesthesia and analgesia 
(Ketoprofen, 5 mg/ kg, SC) a vertical skin incision of 10 mm was performed medially in 
the upper abdomen. Abdominal muscles were split and the peritoneum was opened through 
sharp dissection (Fig. 1.A). The liver was gently elevated with a moist Q-tip to give access 
to the abdominal esophagus. The stomach was lifted extra-corporeally by traction on the 
greater curvature with a forceps. A micro-forceps was positioned underneath the distal 
esophagus to lift it (Fig. 1.B). While the esophagus was stretched by gentle tension on the 
stomach by an assistant, a 30-gauge needle was inserted in the distal part of the esophageal 
wall and tunneled proximally for about 3 mm (Fig. 1.C). Tumor cells, suspended in 20 µl 
Matrigel/animal were injected slowly, resulting in a local bulging (Fig. 1.D). At body 
temperature, Matrigel solidifies within seconds, minimalizing the risk of intra-abdominal 
spilling of tumor cells. The stomach was cautiously repositioned and the abdominal wall 
and skin were closed with a running PDS 6-0 suture. Hartmann solution (500 µl) was given 
SC to prevent dehydration. Animals were followed daily and weighed 2 times per week.  
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Subcutaneous (TTSC) and orthotopic tumor take (TTorth) were defined as the percentage of 
macroscopic tumor nodules (confirmed on histology) on the total number of injections. At 
7 weeks, mice were euthanized and tumors were excised for histopathology. 
 
 
FIGURE 1: Surgical technique of orthotopic injection of tumor cells. (A) Upper abdominal 
median laparotomy in a mouse under general inhalation anesthesia, positioned using tape; (B) The 
stomach is lifted extra-corporal with a forceps. Another forceps (micro-instrument) is positioned 
underneath the esophagus to improve the access; (C) Insertion of a 30 G needle in the distal esophageal 
wall; (D) Injection of tumor cells in Matrigel resulting in a bleb in situ. 
 
MAGNETIC RESONANCE IMAGING 
A subpopulation of mice with orthotopic tumors (OE33 tumor nodules, n= 5) were 
evaluated by magnetic resonance imaging (MRI) at 1, 2, 3, 5, 8 and 12 weeks after tumor 
injection to follow tumor progression. MR images were acquired on a 7T system (Bruker 
PharmaScan 70/16, Ettlingen, Germany) with a mouse body volume coil. Mice were 
anaesthetized with isoflurane (5% induction, 1.5% maintenance, 0.3 L/ min) and warmed 
with a water-based heating blanket. Respiration was monitored using a respiration pad 
underneath the mouse. Anatomical information was obtained with a T2-weighted sequence 
(TurboRARE) with the following parameters: TR 3661 ms, TE 37.1 ms, 109 µm in-plane 
resolution, 30 contiguous transverse slices of 600 µm, and acquisition time 9’1”. Mice were 
euthanized 15 weeks after tumor induction. 
 
IN VIVO SELECTION OF CANCER CELLS 
To obtain subcultures of cell lines that grow well in mice, tumors (SC and orthotopic) were 
excised under sterile conditions and divided into small pieces. Tumor fragments were 
dissociated (gentleMAX Dissociator, Miltenyl Biotec GmbH, Germany) together with a 
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collagenase 1 mg/ ml (Sigma- Aldrich) in PBSD+ mixture to disrupt tissue structures. The 
suspension was filtered through a cell strainer (70 µm) and centrifuged. Cells were seeded 
in T75 falcons and incubated. After 24 hours, non-adherent cells were cleared and replaced 
by fresh culture medium.  
 
TUMOR SAMPLES AND HISTOLOGY 
Tumors were excised fixed with 4% formaldehyde, processed and embedded in paraffin.   
Tumor sections of 5 µm were cut with a microtome (Microm HM355S, Thermo Scientific, 
Rockford, IL, USA). H&E staining and Ki67 staining (ready-to-use DAKO Envision+ 
system- HRP kit (K4011)) were performed according to standard protocols. Slides were 
scanned on 100x and 200x magnification and proliferation indices were determined by an 
overall visual scoring system. Tumors were categorized low, moderate or high proliferative. 




Statistical analysis was performed with GraphPad Prism6 (Graphpad Software, Inc.: La 
Jolla, CA, USA). Mann- Whitney test was used to compare in vitro results of the parental 
and in vivo selected cell line. Fisher’s exact test was used to compare tumor take rates. 
Results were summarized as means with standard deviation (SD) and were considered 
statistically significant when the probability of a type I error was ≤ 0.05.  
 
RESULTS 
CELL CHARACTERIZATION OF OE33 
OE33 cells had an epithelial morphology, characterized by adherent cells, cell-cell contacts 
and a typical formation of islands (Fig. 2.A above). These cell-cell contacts resulted in the 
ability to form compact spheres under Gyrotory shaking (Fig. 2.A middle). On type I 
collagen gels, 21.6% (95% CI [8.12%, 35.04%]) of OE33 cells showed cellular extensions 
invading the matrix (Fig. 2.A under, B left). When seeded in a low density on tissue culture 
substrate, only a limited number of these cells were able to form a colony (mean CFI= 
7.23%, 95% CI [6.24%, 8.23%]) (Fig. 2.B right). Additionally, Western blot was performed 
(Fig. 2.C). OE33 cells expressed cytokeratin, an intermediate filament supporting the 
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epithelial origin of the cancer cell line. Furthermore, cells showed expression of α- and β-
catenin and E- and P-cadherin, proteins important for cell- cell adhesion and tissue 




FIGURE 2: In vitro characteristics of OE33. (A) Above: Cell lines in culture, phase contrast image 
(scale bar= 200 µm); Middle: Sphere formation assay 72 h after initiation, phase contrast image (scale 
bar= 100 µm); Under: Collagen type I invasion assay 24 h after seeding, phase contrast image (scale 
bar= 100 µm), yellow arrows show invasive cells in collagen type I gel. (B) Left: Collagen invasion 
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index (%); Right: colony formation index (%). Single values, mean, standard deviation. (C) Western 
blot of OE33 compared to HCT8/E11 and MDA-MB-231 GFP Luc.  
 
TUMOR DEVELOPMENT WITH OE33 
Four mice were injected subcutaneously bilaterally with OE33 cells (Table 1). These all 
resulted in similar small tumor nodules, but volumes seemed to decrease progressively (Fig. 
3.A). Histologically, nodules consisted of well differentiated tumor cells organized in 
islands and surrounded by infiltrating stromal cells connective tissue (Fig. 3.B-C). They 
were not invasive into surrounding tissues and Ki67 indices were low to moderate (Fig. 
3.D). Two nodules were used for in vivo selection and were confirmed to contain tumor 
cells through that means.  
Twelve mice were orthotopically injected with OE33 cells (Table I). Seven animals 
developed tumor nodules at the distal site of the esophagus without evidence for metastasis 
(liver, diaphragm, peritoneum and omentum were free of lesions) (Fig. 4. A). Tumors were 
located at the submucosal space and were not invasive into surrounding tissue (Fig. 4.B, D). 
They were well differentiated and had a low proliferation index (Fig. 4.C). Three nodules 






FIGURE 3: SC xenograft OE33 tumor. (A) Tumor volumes (mm3) of 7 SC tumors, time after 
injection of tumor cells; (B-C) H&E of SC tumor at different magnifications; (D) Ki67 staining of 
adjacent tumor slide.  
 
 
FIGURE 4: Orthotopic xenograft OE33 tumor. (A) Macroscopic tumor nodule at the distal site of 
the esophagus (yellow arrow). The stomach is pulled downwards with a forceps; (B, D) H&E of tumor 
nodule. E= esophageal lumen. T= tumor nodule. M= muscle layers of the esophageal wall. m= 
esophageal mucosa. The nodule is situated in the submucosal space and does not invade the mucosa. 




TABLE 1: Summary of in vivo experiments. 
 
50 
MRI scans were performed in a subset of mice (n= 5) to follow tumor development (Fig. 5. 
A). At the initial MRI scan 1 week post-tumor induction, all of them showed a clear tumor-
like nodule at the distal site of the esophagus. During follow-up, volumes remained the 
same and at the end 4 out of 5 animals showed a tumor-like nodule on MRI. These were 
confirmed to contain tumor cells microscopically (Fig. 5. B-D). 
 
 
FIGURE 5: MRI images of orthotopic OE33 esophageal tumor. (A) Transverse MRI images at 
different time points (in weeks) after tumor induction. Yellow arrow= tumor nodule; (B) Macroscopic 
tumor (yellow arrow) at distal esophagus, E= esophagus, S= stomach; (C-D) H&E staining of tumor. 
T= tumor nodule. E= esophagus. M= muscle layer of esophageal wall.  
 
CELL CHARACTERIZATION OF OACM5 1.C 
OACM5 1.C cells had two morphological subtypes: a majority of multicellular floating cell 
clusters, and some adherent cells with a fibroblast-like appearance, growing as single cells 
(Fig. 6.A above). These did not form cell-cell contacts and only very few cells were adherent 
to plastic. OACM5 1.C cells were not able to form compact spheres under Gyrotory 
shaking, but formed loose cell clusters with recognition of individual cells (Fig. 6.A 
middle). Furthermore, they were non-invasive into collagen gels (mean 1.38%, 95% CI [-
0.30%, 2.47%]) (Fig. 6.A under, B above) and were not clonogenic (CFI= 0.10%, 95% CI 
[-0.001%, 0.201%]) (Fig. 6.B under). OACM5 1.C cells expressed cytokeratin on Western 
blot supporting the epithelial origin of the cancer cell line. They expressed β-catenin and 
poorly expressed α-catenin but lacked expression of E-cadherin to consolidate cell-cell 
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contacts. OACM5 1.C expressed vimentin representing the mesenchymal characteristics of 
the cell line. (Fig. 6.C)  
 
 
FIGURE 6: In vitro characteristics of OACM5 1.C and OACM5 1.C SC1. (A) Above: Cell lines 
in culture, phase contrast image (scale bar= 200 µm); Middle: Sphere formation assay 72 h after 
initiation, phase contrast image (scale bar= 100 µm); Under: Collagen type I invasion assay 24 h after 
seeding, phase contrast image (scale bar= 100 µm); (B) Above: collagen invasion index (%), single 
values, mean, standard deviation, P= 0.368; Under: Colony formation index (%), single values, mean, 
standard deviation, P< 0.0001. (C) Western blot of OACM5 1.C and OACM5 1.C SC1 compared to 
MDA-MB-231 GFP Luc and HCT8/E11.  
 
TUMOR DEVELOPMENT WITH OACM5 1.C  
Four mice were injected subcutaneously bilaterally with OACM5 1.C cells (Table 1). Four 
out of eight injections resulted in macroscopic tumor nodules. One nodule had an 
exponential growth curve, while the others remained stable (Fig. 7. A). Histology showed 
nodules packed with tumor cells with little infiltrating stromal cells. They were not invasive 
into surrounding tissues and Ki67 staining was overall low to moderate (Fig. 7. B-D). 
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Injection sites that did not develop macroscopic nodules (4/8) resulted in palpable fibrous 
remnants in which some loose tumor cell islands could be identified on histology. One 
nodule was used for in vivo selection and was confirmed to contain tumor cells through that 
means. An additional six mice were orthotopically injected with OACM5 1.C cells (Table 
1). Of 4 mice evaluable, no tumor nodules, metastasis or involved lymph nodes were 
macroscopically visible and histology was negative for tumor cells.  
 
 
FIGURE 7: SC xenograft OACM5 1.C tumor. (A) Tumor volumes (mm3) of 8 SC tumors, time 
after injection of tumor cells. 4 out of 8 injections did not develop tumor nodules; (B-C) H&E of SC 
tumor at different magnifications; (D) Ki67 staining of adjacent tumor slide.  
 
ESTABLISHMENT OF NEW IN VIVO SELECTED CELL LINE 
OACM5 1.C SC1 
OACM5 1.C cells harvested from a SC tumor nodule, were stable through different in vitro 
passages and could be re-injected in mice according to the above protocols. Five mice were 
injected subcutaneously bilaterally with OACM5 1.C SC1 cells, resulting in 10 
macroscopically visible tumors (Table 1). 5 out of 10 were fast growing (Fig. 8. A). 
Histology showed presence of tumor cells in all nodules (Fig. 8. B-C) and Ki67 staining 
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was low to moderate (Fig. 8. D). An additional six mice were injected orthotopically with 
OACM5 1.C SC1 cells, leading to two small macroscopic tumor nodules (Table 1). No 
metastasis were observed. Histology confirmed presence of tumor cells and nodules did not 
invade surrounding tissues (Fig. 9. A-C). In vivo selection of OE33 cells was not successful 





FIGURE 8: SC xenograft OACM5 1.C SC1 tumor. (A) Tumor volumes (mm3) of 10 SC tumors, 
time after injection of tumor cells; (B) H&E staining of SC tumor with close-up (C), packed with 
tumor cells; (D) Ki67 staining of adjacent tumor slide.  
 
COMPARISON OF OACM5 1.C AND OACM5 1.C SC1 
Both cell lines had the same morphological appearance in vitro (Fig. 6.A above) and in vivo 
(Fig. 7 and Fig. 8). Further, they had the same cell line characteristics concerning sphere 
formation and collagen invasion (Fig. 6.A-B). Moreover, cell-cell adhesion and cytoskeletal 
protein expression were similar (Fig. 6.C). Yet, the in vivo selected cell line had higher 
subcutaneous tumor take rates than the parental cell line (TTSC= 100% versus 50% (P< 
0.023) (Fig. 10). This can be related to the significant higher clonogenicity (P< 0.0001) of 




FIGURE 9: Orthotopic xenograft OACM5 1.C SC1 tumor. (A-B) H&E staining of orthotopic 
OACM5 1.C SC1 tumor nodule, situated at the submucosal space. E= esophageal lumen. T= tumor 
nodule. M= muscle layers of the esophageal wall; (C) Ki67 staining of adjacent tumor slide. 
 
FIGURE 10: Tumor take of OACM5 1.C and 
OACM5 1.C SC1. SC and orthotopic tumor take 
were compared between the two cell lines. 
Development of tumors was expressed as a 
percentage of the total amount of implanted tumors: 
OACM5 1.C (SC) (n= 4/8) versus OACM5 1.C SC1 
(SC) (n= 10/10); OACM5 1.C (orth) (n= 0/6) versus 
OACM5 1.C SC1 (orth) (n= 2/6). Subcutaneous 
tumor take was significantly increase with the in vivo 
selected cell line (OACM5 1.C SC1) compared to the 
parental cell line (OACM5 1.C) (P< 0.023). The 
observed increase in orthotopic tumor take was not 
statistically significant (P= 0.4667). 
 
DISCUSSION 
This study investigated the orthotopic growth potential of two generally available EAC cell 
lines, OE33 and OACM5 1.C, and a third cell line obtained through in vivo selection, 
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OACM5 1.C SC1. Additionally, in vitro experiments were performed to better understand 
functional characteristics in relationship with in vivo growth behavior.  
OE33 showed successful orthotopic xenografts in 63.6% (n= 12) of the cases. Nevertheless, 
volumes remained stable during follow-up, as can be seen on the serial MRI scans. 
Subcutaneous tumor take was higher (TTSC= 100%, n= 7) but resulted in similar small 
tumor nodules with stable to decreasing volumes. To our knowledge, only one previous 
study used OE33 cells for orthotopic use. The study was diagnostic and had similar results 
to ours. Small tumors of 2-3 mm in diameter at 4 weeks after injection (n= 5) were seen 
[92]. OE33 seems to be a low aggressive cell line with a high subcutaneous and orthotopic 
tumor take in nude mice, but extremely slow growth pattern. The decreasing subcutaneous 
volumes may be explained by clearance of Matrigel with slow replacement of tumor cells.  
In contrast to the OE33 cell line, OACM5 1.C cells were not able to develop orthotopic 
tumor nodules (TTorth= 0%, n= 6). Also subcutaneous tumor take was low (TTsc= 50%, n= 
8). To improve these poor tumor take rates, a technique of in vivo selection of tumor cells 
was applied. As such, the new cell line OACM5 1.C SC1 was established and successfully 
led to a significant higher subcutaneous tumor take than the parental cell line (100% (n= 
10) versus 50% (n= 8), P< 0.023). Orthotopic tumor take did not differ significantly (33.3% 
(n= 6) versus 0% (n= 6), P= 0.467). Cell lines had similar in vitro characteristics, except 
from the significant increased ability of the in vivo selected cell line to form colonies (P< 
0.0001). The latter may partially explain the increased tumor take rate.  
Another correlation between the in vitro and in vivo results was seen in the invasiveness of 
the cell lines. The investigated EAC cell lines were almost non-invasive in collagen type I 
gels in vitro and none of the xenografts in the mouse experiments invaded the surrounding 
tissues.  
Beside in vivo selection, improved tumor take rates may be reached by simply increasing 
the amount of injected tumor cells. Unfortunately, the injection volume in the esophageal 
wall is limited. As such, the amount of injectable tumor cells is also limited to about 1.5 x 
10^6 cells per injection. This can be bypassed by transplanting a subcutaneous tumor 
fragment on the esophageal wall according to the technique of Gros et al. [93]. An additional 
experiment was performed with transplantation of 1mm3 tumor fragments of a subcutaneous 
OE33 tumor on the esophageal wall of 7 mice. Due to postoperative complications, three 
animals died within the first week postoperative. The remaining 4 did not show any vital 
tumor on the esophageal wall up to 70 days of follow up. We believe this is a technically 
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more difficult procedure, with a low success rate if fragments of slow growing tumor 
nodules are used and concluded this is not beneficial for the investigated cell lines. 
It needs to be mentioned that the development of EAC in this tumor model differs from the 
situation in patients. While the pathogenesis is not yet fully understood, it is believed that 
chronic inflammation of the esophageal mucosa can develop dysplasia and eventually can 
evolve in EAC. As such, gastro-esophageal reflux disease (GERD) is one of the major risk 
factors for developing EAC, besides obesity [85]. In literature, several other models have 
been described, that reflect the clinical situation more closely [88]. On one hand, different 
reflux models have been used: surgical esphagojejunostomy [106] or drinking of caustic 
substances [107]. These reflux models lead to less than 50% cancer development in a time 
period of 6 months making it unreliable for therapeutic studies [88]. On the other hand, the 
use of genetically engineered mouse models (GEMMs) has been investigated. Transgenic 
mice with IL-1β overexpression were shown to develop moderate inflammation by 6 
months, with a small percentage of mice developing high grade dysplasia or EAC after 20-
22 months [107]. Best results with GEMMs were obtained in combination with the caustic 
substance deoxycholate (DCA), where 45% of mice developed EAC after a long follow-up 
period of 15 months [107]. The technique of injecting tumor cells in the esophageal wall is 
considered to be the best option available for the development of a relative rapid and reliable 
orthotopic mouse model.  
Surprisingly, the three investigated EAC cell lines grew more efficient subcutaneously than 
orthotopically. To rule out technical issues with the orthotopic injection method, the 
technique was checked with a highly aggressive ovarian carcinoma cell line, SK-OV-3 Luc 
IP1 cells, that is known to be 100% tumorigenic in Foxn1nu mice, according to previous 
experiments in our research group [108]. Injection of 5 x 105 SK-OV-3 Luc IP1 cells in the 
esophageal wall resulted in 100% tumor take and 100% exponential tumor growth (n= 5), 
confirmed on IVIS, MRI and histology (Fig. 11). After 4 weeks, exophytic tumors of about 
8 mm diameter were observed. We believe the low orthotopic tumor take rates with the 
investigated EAC cells is due to a combination of low aggressive cells and the limited 





FIGURE 11: SK-OV-3 Luc IP1 heterotopic esophageal tumor growth. (A) Weight of mice with 
heterotopic SK-OV-3 Luc IP1 cells at the esophagus; (B) Macroscopic xenograft tumor (=yellow 
arrow) on the distal esophageal wall, with no sign of compression or dilatation of the proximal 
esophagus; (C) T2 weighed MRI, yellow arrow appoints the voluminous tumor; (D-E) H&E at 
different magnifications of a xenograft ovarian tumor at the esophageal wall.  
 
The fact that the OACM5 1.C SC1 experiments are based on cells originating from one 
tumor nodule, could be point of discussion. Nevertheless, the in vivo selection technique is 
a validated technique to improve cell line characteristics (such as metastatic potential or 
take rates [108, 109]). Our aim was not to validate the technique, but to use it to improve 
tumor take rates and to show it can be of use for esophageal cancer models. The OACM5 
1.C SC1 cell line was authenticated by STR assay, was stable through different passages 
and led to increased tumor take rates. The unsuccessful in vivo selection of OE33 was 
probably due to the small amount of tumor cells in the excised tumors and the low 
clonogenic potential of the cells. Repetitions would most probably lead to the same results. 
Finally, the follow-up of esophageal tumor growth in mice is challenging (i.e. due to its 
location). Performing a laparotomy at different time points is easy, fast and does not require 
specialized tools or knowledge. However, this causes intra-abdominal adhesions, making 
esophageal exposure more difficult after every laparotomy and could cause an inflammatory 
reaction influencing tumor development. MRI imaging was already confirmed to be feasible 
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and accurate for the follow-up of esophageal cancer in mice [93, 100, 101]. In this study, a 
dedicated small animal MRI scanner was used, leading to detailed images. Tumor nodules 
could be defined precisely as hyper-intense nodular structures, at a fixed location, slightly 
proximal of the gastro-esophageal junction. Also, the volumes of nodules could be 
measured accurately. However, MRI is not able to differentiate tumor tissue from 
inflammatory scar tissue or residual Matrigel. If volumes increase, viable tumor cells are 
plausible. If not, presence of tumor cells cannot be assured. It would be interesting to 
transfect the investigated EAC cell lines with luciferase, like shown by Gros et al. [93], to 
perform in vivo fluorescence imaging in case of stable nodules and be able to differentiate 
viable tumor cells from scar tissue and Matrigel. 
This study can be of interest for future experiments. Especially the OE33 cell line is 
appropriate for orthotopic injection for diagnostic studies on EAC. Yet, some limitations, 
such as low aggressive cells, slow growth pattern and different etiology in patients should 
be kept in mind. It must be mentioned that this was the first study to describe growth 
behavior of OACM5 1.C in mice. OACM5 1.C had a poor tumor take rate at an orthotopic 
and ectopic site. The in vivo selected cell line OACM5 1.C SC1 showed higher 
subcutaneous take rates. The use of a more immunodeficient mouse strain (NOD SCID 
mice) could improve tumor take and should be considered for future research with these 
low aggressive cell lines.  
 
CONCLUSION 
Little research is available about esophageal cancer, especially the EAC subtype, which is 
the more prevalent type in the Western world. Our paper provides an orthotopic and 
subcutaneous xenograft EAC model in mice, which will hopefully contribute to further 
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 The following researchers contributed to the pilot study: 
Melsens E, De Vlieghere E, Descamps B, Vanhove C, Kersemans K, De Vos F, 
Goethals I, Brans B, De Wever O, Ceelen W, Pattyn P. 
 
ABSTRACT 
Aim: In this chapter, we aimed to evaluate the feasibility of 18F-FAZA PET/CT in the 
orthotopic and subcutaneous xenograft EAC models described in Chapter 3.  
Methods: Subcutaneous tumors (OACM5 1.C SC1, human EAC) (n= 6) and esophageal 
tumors (SK-OV-3 IP1, human ovarian cancer) (n= 3) were used. The hypoxia tracer 18F-
FAZA (37 MBq) was injected in the tail vein of tumor bearing mice and PET/CT was 
performed 3 hours after tracer injection (30 min acquisition). Images were analyzed with 
AMIDE software and tumor to background ratios were calculated. Mice were euthanized 
on the same day of imaging, 1 hour after pimonidazole injection (IP). Tumors were excised 
and examined histologically. 
Results: All subcutaneous tumors could be delineated on FAZA PET/CT and T/B rates 
could be calculated. The esophageal tumors could not be delineated due to insufficient soft 
tissue resolution on the CT scan and abundant background tracer activity in the liver region. 
Further, background activity was seen in the gall bladder, gastro-intestinal tract and urinary 
bladder. 
In the previous chapter, we described the development of an orthotopic and 
subcutaneous EAC tumor model in mice that can be used to investigate our 
first research question ‘Can hypoxia imaging with 18F-FAZA PET/CT serve 
as a predictive biomarker and as a guidance for hypoxia targeting?’. We 
tested the feasibility of 18F-FAZA PET/CT in both tumor models in a pilot 
study, which is described in this chapter. 
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Conclusion: 18F-FAZA PET/CT imaging is feasible in the subcutaneous OACM5 1.C SC1 
model, but not in the orthotopic model.  
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MATERIALS AND METHODS 
SUBCUTANEOUS (SC) XENOGRAFTS 
To visualize hypoxia with 18F-FAZA PET/CT, a minimum tumor volume is needed. Most 
studies set the absolute minimum at a diameter of 5-10 mm or a volume of 200 mm3 [62, 
79, 110, 111]. We used SC OAMC5 1.C SC1 tumors, 7 weeks after tumor inoculation. 
According to the results of Chapter 3 these should have reached a volume of 100-200 mm3.  
 
ORTHOTOPIC XENOGRAFTS 
The orthotopic EAC xenograft model with OE33 provided slow growing and small tumors, 
which is not ideal for this pilot. Therefore, we opted for the SK-OV-3 Luc IP1 ovarian cell 
line, described in Chapter 3 in the Discussion section, in which macroscopic bulky tumors 
were reached at the distal site of the esophagus, 5 weeks after tumor inoculation.  
For more details on animals or cell lines, see Materials and Methods section of Chapter 3. 
 
18F-FAZA PET-CT 
The radiosynthesis of 18F-FAZA was performed on a Synthra RNplus module (Synthra 
GmbH, Hamburg, Germany) using a fully automated procedure that was based on standard 
procedures [112, 113]. The precursor for the radiosynthesis, 1-(2,3-diacetyl-5-tosyl-(α-d-
arabinofuranosyl)-2-nitroimidazole, was purchased from ABX GmbH (Radeberg, 
Germany) and all other required reagents and solvents were acquired from Sigma-Aldrich 
(Overijse, Belgium). 
Mice were anaesthetized and a target activity of 37 MBq of 18F-FAZA was injected in the 
tail vein. Three hours after injection and under anesthesia, the animals were positioned on 
a heated animal bed of a small animal PET/CT scanner (TriFoil Imaging, Triumph II, 
Northridge, CA, USA). CT projection data were acquired using the following parameters: 
256 projections, detector pixel size 50 µm, focal spot size 100 µm, tube voltage 50 kV, tube 
current 640 µA, and a field-of-view of 90 mm. A 30 minutes PET scan was acquired in list 
mode, with a 75-mm axial field-of-view and a 1.3-mm spatial resolution, on the same 
scanner and without moving the animal. CT images were analytically reconstructed using a 
filtered back projection reconstruction algorithm (Cobra Version 7.3.4, Exxim Computing 
Corporation, Pleasanton, CA) into a 256x256x512 matrix with 200 µm isotropic voxel size. 
The acquired PET images were reconstructed into a 200x200x64 matrix by a 2D maximum 
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likelihood expectation maximization (MLEM) algorithm (LabPET Version 1.12.1, TriFoil 
Imaging®, Northridge, CA) using 50 iterations and a voxel size of 0.5x0.5x1.175 mm3 (x, 
y, z). Each resultant CT image is inherently co-registered with the corresponding PET scan. 
PET and CT images were imported into A Medical Image Data Examiner (AMIDE) [114], 
where tumor-to-background ratios (T/B) were calculated as the mean tumor uptake divided 
by the background activity. Mean tumor uptake was quantified into a volume-of-interest 
that was semi-automatically delineated as the activity >40% of the maximum activity using 
the 3D-isocontour tool, similar to Tran et al. [78], and a sphere with radius 1.5 mm was 
delineated in the foreleg muscle as background tissue. 
 
MRI 
See Chapter 3, Materials and Methods. 
 
IMMUNOHISTOCHEMISTRY 
The exogenous hypoxia marker pimonidazole (Hypoxyprobe, MA, USA) was administered 
1 hour before sacrifice (60 mg/kg, IP) and stained on formalin-fixed paraffin-embedded 
tumor sections (5 µm) with the Hypoxyprobe anti-pimonidazole mouse IgG1 monoclonal 
primary Ab (HP1-100 Kit) (1/50, 1 h, RT) and the LSAB+ System-AP kit (DAKO K0675). 
 
RESULTS 
A total of 6 animals were imaged: 3 mice with bilateral OACM5 1.C SC1 tumors (6 tumors 
in total) and 3 mice with a SK-OV-3 Luc IP1 tumor at the distal site of the esophagus. 
Overall, a high background staining was seen in the liver, gall bladder, small and large 
intestine and the urinary bladder (Fig. 1). 
 
SC XENOGRAFTS 
All 6 tumors could be delineated on the PET/CT images and SUV values and T/B ratios 





FIGURE 1: 18F-FAZA PET/CT. 
Coronal images of 18F-FAZA PET/CT scans of 2 mice (A and B) illustrating the main regions of 
background activity: *= gall bladder; L= liver; GI= small and large intestine; U= urinary bladder. 
 
 
TABLE 1: Results of 18F-FAZA PET/CT imaging. 
SUV= Standardized uptake value. Tracer uptake is quantified as percentage of the totally injected 
activity (%ID/g) and standardized to the animals’ weight. T/B= Tumor to background. Mean tumor 






















Tumor 1 Yes 97.0 +/- Yes 0.09 1.79 
Tumor 2 Yes 78.8 + Yes 0.09 2.40 
Tumor 3 Yes 156.8 / Yes 0.10 1.59 
Tumor 4 Yes 91.7 + Yes 0.13 3.90 
Tumor 5 Yes 219.7 + Yes 0.15 2.13 
Tumor 6 Yes 231.2 + Yes 0.17 2.73 
ORTHOTOPIC 
Tumor 1 Yes 95.16 + No / / 
Tumor 2 Yes 116.3 + No / / 





FIGURE 2: 18F-FAZA PET/CT in SC xenografts. 
(A-B) Pimonidazole staining (=brown) of tumor section at different magnifications ((A) 40x and (B) 
400x). Hypoxia is distributed heterogeneously in the tumor. (C-E) Transverse slices with mice in 
prone position on the PET/CT bed with right SC tumor on the hind leg. (C) CT image with tumor 
delineated spherically (yellow). (D) 18F-FAZA PET image. An irregular hypoxic area is visualized 
at this level of the tumor. The intense 18F-FAZA signal in the middle of the image is background 
activity from the gastro-intestinal tract. (E) Overlay 18F-FAZA PET/CT. The PET data exterior to 
the ROI was erased. Orange= ROI >40% isocontour.  
 
ORTHOTOPIC XENOGRAFTS 
Three mice with SK-OV-3 Luc IP1 tumors at the distal site of the esophagus were imaged 
5 weeks after tumor inoculation (Fig. 3). Tumor volumes were determined on MRI at the 
day of the 18F-FAZA PET/CT. Despite the clear presence of a voluminous tumors, it was 
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impossible to identify the tumors on PET/CT. First, soft tissue resolution on the CT was 
insufficient to differentiate the tumor from the neighboring tissues. Second, the intense 
background staining in the liver compromised tumor visualization on the PET images. As 
a result, no quantification of tumor hypoxia could be done on the 18F-FAZA PET/CT (Table 
1). Yet, the presence of tumor hypoxia was confirmed histologically with pimonidazole 
staining in all 3 tumors (Fig. 3). 
 
 
FIGURE 3: 18F-FAZA PET/CT in orthotopic xenografts. 
(A-B) Pimonidazole staining (=brown) of tumor section at different magnifications ((A) 40x and (B) 
400x).  A small hypoxic zone is identified in the upper right quadrant of the tumor. (C) Transverse 
slice of MRI image. Tumor mass is delineated in yellow. (D-E) Transverse and coronal image of 
overlay 18F-FAZA PET/CT scan. The esophageal tumor mass clearly visible on MRI, could not be 
identified on the 18F-FAZA PET/CT scan. 
 
DISCUSSION 
Overall, high background activity was observed in the liver, gall bladder, small and large 
intestine and urinary bladder, which is due to the pharmacokinetic properties of the tracer. 
18F-FAZA is excreted through the gall bladder and gastro-intestinal tract, after hepatic 
 
68 
metabolization, and directly through the kidneys and the urinary bladder [62]. The SC 
tumors were localized outside these regions and could be visualized and delineated 
successfully on the 18F-FAZA PET/CT in all 6 tumors. The orthotopic xenografts were 
located near the liver, making visualization impossible.  
This raises the question whether translation to the clinical setting would be feasible. 
First, these experiments showed that the small dimensions of the mice, together with the 
low soft tissue resolution on the small animal PET/CT, were a primary cause of difficult 
tumor visualization. In the clinical setting, all esophageal cancer patients undergo CT-
imaging as part of the standard staging modalities. Esophageal tumors are delineated more 
easily on CT images of patients than in mice which will be a first factor in favor of the 
clinical setting. 
Second, not all tumors will be located in the field of background activity (liver). This tumor 
model represented esophageal adenocarcinomas (EAC) and was chosen because this has 
become the main subtype in the United States and Northern and Western Europe [103]. 
EAC is typically located at the lower 1/3 of the esophagus and at the gastro-esophageal 
junction [115], and thus near the liver. The second most common subtype is esophageal 
squamous cell carcinoma (ESCC). These tumors are mainly located in the proximal 2/3 of 
the esophagus [115], and thus outside any background activity fields, as can be seen on the 
scans (Fig. 1 and 3). The higher the tumor will be located, the easier visualization will be. 
 
CONCLUSION 
18F-FAZA PET/CT imaging is feasible in the subcutaneous OACM5 1.C SC1 model, but 
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CHAPTER 5: PREDICTIVE VALUE OF 18F-FAZA PET/CT 




 This chapter is based on the following article: 
Melsens E, De Vlieghere E, Descamps B, Vanhove C, Kersemans K, De Vos F, 
Goethals I, Brans B, De Wever O, Ceelen W, Pattyn P. Hypoxia imaging with 18F-




Background: Esophageal cancer is an aggressive disease with poor survival rates. Standard 
treatment encompasses neoadjuvant chemoradiation (locally advanced stage). Response to 
neoadjuvant therapy is highly variable and difficult to predict. As it is known that tumor 
hypoxia is correlated with treatment resistance and worse prognosis in solid tumors, this 
could be an interesting predictive factor for esophageal cancer. By imaging hypoxia with 
18F-FAZA PET/CT, we aimed to predict treatment response of esophageal adenocarcinoma 
(EAC) xenografts. Further, we investigated hypoxic radioresistance and the radiosensitizing 
effect of the hypoxia modifier nimorazole in vitro and in vivo.  
Methods: In vitro MTS cell proliferation assays were performed under normoxic and 
hypoxic conditions with 8 treatment groups: control, nimorazole, irradiation (5, 10 or 20 
Gy) with or without nimorazole. In vivo, subcutaneous xenografts were induced in the hind 
legs of nude mice (human EAC cell line OACM5 1.C SC1). Mice were divided in 3 
In chapter 3, we described the development of an orthotopic and 
subcutaneous EAC model in mice. Chapter 4 showed that only the 
subcutaneous model was feasible for 18F-FAZA PET/CT hypoxia imaging. 
In this chapter, we investigated the first research question ‘Can hypoxia 
imaging with 18F-FAZA PET/CT serve as a predictive biomarker and as a 
guidance for hypoxia targeting?’ in our subcutaneous EAC tumor model. 
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treatment groups: (A) control, (B) radiotherapy (RT) (5 Gy/d during 5 days) and (C) 
combination (nimorazole (200 mg/kg/d, IP) 30 min before RT). 18F-FAZA PET/CT was 
performed before and after treatment and tumor to background (T/B) ratios were calculated. 
Tumors were measured daily with calipers and relative tumor growth (RTG) was calculated. 
Tumor sections were examined histologically (hypoxia, DNA double-strand breaks (DSB), 
apoptosis and proliferation).  
Results: A T/B ≥ 3.59 on pretreatment 18F-FAZA PET/CT was predictive for worse RT 
response in xenograft EAC tumors (sensitivity 92.3%, specificity 71.4%). Radiation 
induced growth inhibition was significantly less in hypoxic tumors (T/B ≥ 3.59) than 
normoxic tumors (T/B < 3.59) (P= 0.0011). Pre-treatment with nimorazole significantly 
decreased in vitro hypoxic radioresistance (P< 0.01) and improved in vivo RT induced 
proliferation inhibition in hypoxic tumor areas (Ki67, P= 0.064).  
Conclusions: 18F-FAZA PET/CT is predictive for RT response in an EAC xenograft model. 





Esophageal cancer is an aggressive disease with poor survival rates. Patients are mostly 
diagnosed in a locally advanced stage and treated with neoadjuvant chemoradiation 
followed by surgery [82]. Response to chemoradiation is highly variable with a pathological 
complete response (pCR) in about 30%, but presence of residual carcinoma in the remaining 
70% [116]. Therefore, identification of imaging biomarkers that allow to predict response 
to chemoradiation is an important challenge.  
An attractive predictive factor is tumor hypoxia that is present in up to 60% of locally 
advanced solid tumors. It has been proven to be an independent negative predictive and 
prognostic factor and has been correlated with chemoresistance, radioresistance, 
invasiveness, propensity to metastasize, and genomic instability [6]. Also in esophageal 
cancer, hypoxia has been correlated with worse outcomes. Histologic examination of 
carbonic anhydrase 9 (CAIX) and hypoxia-inducible factor 1-alpha (HIF-1α), two factors 
that are overexpressed in hypoxic conditions, were correlated with worse outcomes and 
hypoxia imaging with 18F-FETNIM (fluoroerythronitroimidazole) positron emission 
tomography (PET) showed that tracer uptake might be predictive for treatment response in 
esophageal cancer [83, 117, 118]. 
Here, 18F-FAZA PET (fluoroazomycin arabinoside) was used to image and quantify tumor 
hypoxia and investigate its predictive potential in esophageal cancer. PET imaging has the 
advantages that it is non-invasive, it can be repeated and it gives a 3D-image of the hypoxia 
distribution [54]. 18F-FAZA is a second generation 2-nitroimidazole with superior 
pharmacokinetics compared to 18F-FMISO (fluoromisonidazole), resulting in a better 
tumor-to-background ratio [64]. The tracer entrapment is based on a reduction of the NO2-
group followed by continued reduction under hypoxic conditions and eventually covalent 
binding to intracellular macromolecules [54]. 18F-FAZA PET already showed to be 
predictive for treatment response in preclinical models of rhabdomyosarcoma and breast 
carcinoma [78, 79]. Clinically, FAZA imaging has been studied in non-small cell lung 
cancer and head and neck squamous cell cancer, while trials are ongoing in rectal, lung, 
cervix, and prostate carcinoma (ClinicalTrials.gov: NCT02624115, NCT02701699, 
NCT01989364, NCT01567800). 
Further, we investigated whether this tumor hypoxia, diagnosed on 18F-FAZA PET, could 
be modified and eventually enhance radiation response. We focused on the radiosensitizer 
nimorazole because it is easy applicable, has few side effects and is already part of daily 
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practice in Denmark for HNSCC patients [35] (DAHANCA guidelines). It is a 5-
nitroimidazole and mimics oxygen in the radiochemical process by promoting fixation of 
free radicals [32].  
In summary, this study investigated the predictive value of 18F-FAZA PET/CT for hypoxia-
induced radioresistance in EAC xenografts and the radiosensitizing effect of nimorazole. 
 
MATERIALS AND METHODS 
CELL LINE 
OACM5 1.C SC1 was established through in vivo selection from the parental cell line 
OACM5 1.C cell line, a human esophageal adenocarcinoma (EAC) cell line, as described 
previously [119], and was authenticated by short tandem repeat DNA profiling. This cell 
line was preferred over the parental cell line because it has increased tumor take rates. Cells 
were cultured at 37°C in 5% CO2 humidified atmosphere in RPMI 1640 Medium (Life 
Technologies) supplemented with GlutaMAX™-I (Life Technologies), 10% fetal bovine 
serum and penicillin-streptomycin. 
 
MTS ASSAY 
Cells were seeded (8x105) in T25 flasks and incubated overnight (ON) at normoxic (5% 
CO2 in air) or hypoxic (Anaerobic Work Station, Baker Ruskinn, gas mixture 80% N2, 10% 
CO2, 10% H2) conditions. Hypoxia was confirmed with an anaerobic indicator (BR0055, 
ThermoScientific). Treatment was given 24 h after seeding. Flasks of the hypoxic group 
were closed in the anaerobic station to ensure hypoxia at the moment of irradiation. One 
dose of 5, 10 or 20 Gy was given, with or without pre-treatment with nimorazole (30 min 
before irradiation, 0.2 mg/mL in PBS). Controls received 100 µL PBS. RT was applied 
using the small animal radiation research platform (SARRP). The voltage of the X-ray 
source was fixed at 220 kV with a tube current of 13 mA, emitted from the 3 mm focal spot 
and filtered by a copper filter of 0.15 mm. A vertical radiation beam of 10x10 cm2 was used 
that permitted simultaneous irradiation of 2 T25 falcons. Flasks were further incubated 
under standard conditions (37°C in 5% CO2 humidified atmosphere) and MTS assay (3-(4, 
5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) 
was performed 72 hours after treatment. MTS Reagent Powder (CellTiter 96® Aqueous 
MTS (Promega)) was dissolved at 2mg/mL in PBSD+. PMS (phenazine methosulfate, 
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dissolved at 0.92 mg/mL in PBSD+) was added at a concentration of 1/20 and 1 mL of the 
solution was added to each flask. After 90 min of incubation at 37°C and 5% CO2, 
absorbance was measured with Paradigm (490 nm) (SPECTRAMax Paradigm, Molecular 
Devices, USA). Cell viability was calculated relative to controls (%). Experiments were 
performed in duplicate and repeated 3 times (n= 3x2). An additional MTS assay was 
performed in a control group on the day of treatment (24 hours after seeding) to quantify 
cell viability at that time point. 
 
ANIMALS 
Animal experiments were approved by the Animal Ethical Committee of Ghent University, 
Belgium (ECD 14/82). Athymic mice (Foxn1nu male) were obtained from Envigo, the 
Netherlands, and were kept under environmentally controlled conditions (12 h normal 
light/dark cycle, 20-23°C and 50% relative humidity) with food and water ad libitum. 
Inhalation anesthesia was performed with isoflurane (Abbott, Belgium), 5% induction, 
1.5% maintenance, 0.3 L/min. Mice were euthanized by cervical dislocation under 
anesthesia one day post-treatment or when humane endpoints were reached.  
 
TUMOR MODEL AND TREATMENT 
At 5 weeks of age, 3 x 106 cancer cells suspended in 100 µl of Matrigel were injected 
subcutaneously in both hind legs under anesthesia. Tumors were grown for 7 weeks. 
Tumors with a minimum volume of 150 mm3 were included and divided into 3 treatment 
groups. Daily treatment was given for 5 consecutive days: (A) Control (600 µl NaCl 0.9% 
intraperitoneally (IP)) (N= 5, n= 7), (B) RT (5 Gy/d) (N= 11, n= 20), (C) Combination 
(nimorazole (200 mg/kg/d IP) given 30 min before RT) (N= 13, n= 21). N= number of mice, 
n= number of tumors. Nimorazole (Adooq Bioscience LLC, USA) was dissolved in NaCl 
0.9% at 10 mg/mL on the day of administration. The dosage and timing was according to 
previous literature [120]. RT was applied using the SARRP with X-ray source parameters 
as described above. A pair of parallel-opposed (anterior-posterior) radiation beams of 10x10 
mm2 were used. Mice were anesthetized and positioned on the bed of the SARRP. Guided 
by lasers, the bed was moved to position tumors at the isocenter of the beam. To allow 
parallel- opposed beam irradiations, mice were turned around when half of the dose was 
given. Doses of 5 Gy (2x2.5 Gy) were delivered daily during 5 consecutive days. Tumor 
nodules were measured daily with calipers and volumes were calculated according to the 
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following formula: 𝑉 = (𝑙𝑒𝑛𝑔𝑡ℎ × 𝑤𝑖𝑑𝑡ℎ)3/2 × 𝜋/6. Relative tumor growth (RTG) was 
calculated as the ratio of the volume at the day of euthanasia to the volume before treatment. 
 
18F-FAZA PET-CT 
The radiosynthesis of 18F-FAZA was performed on a Synthra RNplus module (Synthra 
GmbH, Hamburg, Germany) using a fully automated procedure that was based on standard 
procedures [121, 122]. The precursor for the radiosynthesis, 1-(2,3-diacetyl-5-tosyl-(α-d-
arabinofuranosyl)-2-nitroimidazole, was purchased from ABX GmbH (Radeberg, 
Germany) and all other required reagents and solvents were acquired from Sigma-Aldrich 
(Overijse, Belgium). 
18F-FAZA PET/CT was performed one day before treatment. Mice were anaesthetized and 
a target activity of 37 MBq of 18F-FAZA (mean 37 MBq, SD 1.85) was injected in the tail 
vein. Three hours after injection and under anesthesia, the animals were positioned on a 
heated animal bed of a small animal PET/CT scanner (TriFoil Imaging, Triumph II, 
Northridge, CA, USA). CT projection data were acquired using the following parameters: 
256 projections, detector pixel size 50 µm, focal spot size 100 µm, tube voltage 50 kV, tube 
current 640 µA, and a field-of-view of 90 mm. A 30 minutes PET scan was acquired in list 
mode, with a 75-mm axial field-of-view and a 1.3-mm spatial resolution, on the same 
scanner and without moving the animal. CT images were analytically reconstructed using a 
filtered back projection reconstruction algorithm (Cobra Version 7.3.4, Exxim Computing 
Corporation, Pleasanton, CA) into a 256x256x512 matrix with 200 µm isotropic voxel size. 
The acquired PET images were reconstructed into a 200x200x64 matrix by a 2D maximum 
likelihood expectation maximization (MLEM) algorithm (LabPET Version 1.12.1, TriFoil 
Imaging®, Northridge, CA) using 50 iterations and a voxel size of 0.5x0.5x1.175 mm3 (x, 
y, z). Each resultant CT image is inherently co-registered with the corresponding PET scan. 
PET and CT images were imported into A Medical Image Data Examiner (AMIDE) [114], 
where tumor-to-background (T/B) ratios were calculated as the mean tumor uptake divided 
by the background activity. Mean tumor uptake (Bq/mL) was quantified in a volume-of-
interest that was semi-automatically delineated as the activity >40% of the maximum 
activity using the 3D-isocontour tool, similar to Tran et al. [123], and a sphere with radius 
1.5 mm was delineated in the foreleg muscle as background tissue. In a subset of mice (RT: 
n=7; combination: n=6), an additional 18F-FAZA PET/CT was performed after treatment to 
evaluate the influence of treatment on hypoxia status. 
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TUMOR SAMPLES AND HISTOLOGY 
Consecutive 5µm sections of formaldehyde-fixed paraffin-embedded tumors were 
prepared. Standard H&E staining was performed and necrotic areas were excluded for 
further analysis. The hypoxia marker pimonidazole, administered 1 hour before sacrifice 
(60mg/kg, IP, Hypoxyprobe, USA), was stained with Hypoxyprobe anti-pimonidazole 
mouse IgG1 monoclonal Ab (HP1-100 Kit) (1/50, 1 h, RT) and the LSAB+ System-AP kit 
(DAKO K0675). Ki67 staining was performed with the primary rabbit monoclonal anti-
human/mouse/rat anti-Ki67 Ab ([SP6] Abcam 16667) (1/100, ON, 4°C) and the labelled 
polymer HRP anti-rabbit secondary Ab (Dako, K4011) (40 min, RT). Proliferation indices 
(fraction of Ki67+ cells/total cells) were calculated in normoxic and hypoxic regions, 
according to pimonidazole staining (magnification 400x, 3x2 hotspots/tumor) (ImageJ 
(ImmunoRatio)). γ-H2AX was stained to evaluate DNA-DSB and confirm irradiation. The 
primary rabbit polyclonal anti-human/mouse anti- γ-H2AX Ab (Bethyl IHC-00059) 
(1/3000, ON, 4°C), the polyclonal goat anti-rabbit biotinylated secondary Ab (E0432) 
(1/200, 30 min, RT) and streptavidine-HRP (1/200, 30 min, RT) were used. Number of foci 
per nucleus (mean) were determined (magnification 400x, 5 at random areas, 15 cells per 
area). As last, cleaved caspase-3 (Asp 175) was stained with the primary rabbit monoclonal 
anti-mouse/human/rat anti-Asp175 Ab (Cell Signaling Technology, ab#9661) (1/400, ON, 
4°) and the labelled polymer HRP anti-rabbit secondary Ab (Dako, K4011) (30 min, RT). 
Sections were scanned (100x and 200x magnification) and apoptotic indices were 
determined by an overall visual scoring system: 0 means no staining and 10 means full 
staining.  




Statistical analysis was performed with GraphPad Prism6 (Graphpad Software, Inc.: La 
Jolla, USA). Data was tested for normality (Shapiro-Wilk), analyzed with the Mann-
Whitney U test (non-parametric) or t-test (parametric) and summarized as medians or means 
with standard deviation (SD). ID50 values of the MTS-assay were calculated with non-
linear regression analysis (log(inhibitor) vs. normalized response). The cut-off T/B ratio to 
predict treatment response was determined with ROC-analysis. T/B ratios of pre- and post-
treatment scans were compared with the Wilcoxon matched-pairs signed rank test. Results 
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were considered statistically significant when the probability of a type I error was ≤ 0.05. 
P-values were abbreviated as *= P <0.05, **= P <0.01, ***= P <0.001, ****= P <0.0001. 
 
RESULTS 
IN VITRO EFFECTS OF HYPOXIA AND NIMORAZOLE ON RT 
RESPONSE 
Cell viabilities were analyzed 72 h after RT and represented the net result of cell growth 
and proliferation, and cell cycle arrest and apoptosis. As expected, RT was less efficient 
under hypoxic conditions, illustrated by an upwards movement of the dose-response curve 
(Fig. 1A). The ID50 was doubled (11.48 Gy versus 23.03 Gy) and cell viabilities were 
significantly higher for all radiation doses (5 Gy: P= 0.0004; 10 Gy: P= 0.0012; 20 Gy: P= 
0.0012) (Fig. 1C, Suppl Fig. 1). Hypoxia also induced a steepening of the dose-response 
curve (HillSlopeNorm= -0.64 (95%CI [-0.77; -0.51]) and HillSlopeHypox= -1.32 (95%CI [-1.67 




FIGURE 1: In vitro effects of hypoxia and nimorazole on radiotherapy (RT) response. 
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(A-B) Normoxia;  Hypoxia;  Normoxia + nimorazole;  Hypoxia + nimorazole. 
(A) Dose-response curve of MTS-assay with RT doses (x-axis, logarithmic) and cell viabilities (y-
axis, mean, SD, non-linear regression fitted curve) relative to controls (0 Gy, cell viability=100%). 
Dotted line= cell viability at the day of treatment. (B) Effect of nimorazole on RT response in hypoxic 
conditions. X-axis: RT doses (5, 10 or 20 Gy) with (+) or without nimorazole. Y-axis: cell viabilities 
relative to controls (single values, medians). (C) Parameters derived from the dose-response curve. 
ID50 values represent the required radiation dose to inhibit 50% of the cell viability. 
 
Nimorazole induced a radiosensitization of hypoxic cancer cells, represented by a 
downward movement of the dose-response curve under hypoxic conditions (Fig. 1A). 
Nimorazole significantly reduced treatment resistance for irradiation with 5 and 10 Gy (P= 
0.0087 and P= 0.0087) (Fig. 1B), but did not enhance radiation response with 20 Gy, nor 
did it reduce the ID50 value (Fig. 1C). Further, nimorazole had no effect on RT efficacy in 
normoxic conditions. 
 
HYPOXIC RADIORESISTANCE AND RADIOSENSITIZING 
EFFECT OF NIMORAZOLE IN EAC XENOGRAFTS 
Cancer cell proliferation was significantly reduced by RT and combination treatment in 
normoxic tumor areas compared to controls (P= 0.0012 and P= 0.0022) (Fig. 2A, 2D). 
Hypoxic areas were resistant to RT with significant higher proliferation indices than in 
normoxic areas (P= 0.0025). Pre-treatment with nimorazole radiosensitized hypoxic cancer 
cells by reducing the proliferation indices in hypoxic tumor areas (trend, P= 0.064) and not 
in normoxic areas (Fig. 2A, 2D).  
Irradiation significantly induced DNA-DSB compared to controls (P< 0.0001) (Fig. 2B, 
2D). A minority of this DNA-damage led to cancer cell apoptosis. Controls scored 0-2, 
whereas 57% (8/14) of the irradiated tumors scored higher (3-5) (Fig. 2C-D). However, no 
tumors scored higher than 5. No difference between normoxic and hypoxic tumor regions 
was observed for DNA-DSB or apoptosis (Fig. 2D). 
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FIGURE 2: Hypoxic radioresistance and radiosensitizing effect of nimorazole in EAC 
xenografts. 
 = Control;  = RT;  = Combination (RT+). (A) Cancer cell proliferation indices from Ki67 
staining (single values, mean, SD). Normoxia/hypoxia was defined by co-localization of 
pimonidazole staining on consecutive sections. (B) Mean DNA-DSB/cancer cell nucleus, resulting 
from γ-H2AX staining (single values, mean, SD). (C) Number of tumors (%) for every apoptotic index 
(0-10) resulting from the cleaved caspase-3 staining. (D) Pimonidazole, γ-H2AX, cleaved caspase-3 
and Ki67 staining of consecutive sections. Representative pictures of each treatment group. Irradiation 
caused DNA-DSB and apoptosis in all treatment groups with no difference between normoxic and 
hypoxic areas. There was less Ki67 staining in normoxic than hypoxic RT treated areas, representing 
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18F-FAZA PET/CT AS A PREDICTIVE BIOMARKER 
Radiosensitive and radioresistant tumors were identified retrospectively based on RTG. 
Tumors that regressed after RT (RTG <100%) were defined radiosensitive (35%, n= 13) 
and tumors that continued growing (RTG >100%) radioresistant (65%, n= 7) (Fig. 3A). Pre-
treatment 18F-FAZA uptake (T/B ratios) was significantly higher in radioresistant tumors 
than in radiosensitive tumors (P= 0.046, Fig. 3B, 3D), demonstrating that more hypoxic 
tumors are more resistant to RT than less hypoxic tumors. ROC-analysis was performed to 
identify a cut-off value for predicting RT response with 18F-FAZA PET/CT, which showed 
that a T/B of 3.59 predicted treatment response with the highest sensitivity and specificity 
(92.3% and 71.4% respectively, AUC 0.75). Based on pre-treatment 18F-FAZA PET/CT, 
tumors were divided in normoxic (T/B < 3.59) and hypoxic (T/B ≥ 3.59). Irradiation 
inhibited tumor growth significantly better in normoxic tumors compared to hypoxic tumors 
(P= 0.0011) (Fig. 3C) and nimorazole seemed to improve tumor growth control in hypoxic 
tumors, but not significantly (Fig. 3C). 
 
TUMOR REOXYGENATION AFTER RADIOTHERAPY 
T/B ratios were significantly reduced by RT (P= 0.047) and combination treatment (P= 
0.031) (Fig. 4A, 4C). This reduction did not differ between RT or combination treatment 
(Fig. 4B) and no link was observed between reoxygenation status and treatment response 
(Fig. 4A). Although 3/4 hypoxic tumors reoxygenated, all 4 were radioresistant (Fig. 4A, 
red). Also after combined treatment 2 out of 2 hypoxic tumors reoxygenated, while one was 





FIGURE 3: Predictive value of 18F-FAZA PET/CT. 
(A) Relative tumor growth (RTG) of RT treated tumors (mean, SD). X-axis: time in days after start 
of treatment. Grey curve: tumors that continued growing (RTG at day 5 >100%= radioresistant, n= 
7). Black curve: tumors that regressed (RTG at day 5 <100%= radiosensitive, n= 13). (B) Pre-
treatment 18F-FAZA uptake of RT treated tumors, T/B ratios (single values, mean, SD). X-axis: 
tumors that regressed (radiosensitive) and tumors that continued growing (radioresistant) after RT. 
(C) RTG of EAC xenografts (single values, mean, SD). Hypoxia status was defined by 18F-FAZA 
PET/CT: T/B < 3.59 = normoxic; T/B ≥ 3.59 = hypoxic. (C) Transverse slices at the level of the hind 
legs with mice in prone position. Left: 18F-FAZA PET images with subcutaneous EAC tumors 
delineated spherically (orange). Middle: corresponding CT images. Right: Overlay 18F-FAZA 
PET/CT. The PET data exterior to the ROI’s was erased. Orange= ROI >40% isocontour. Upper 
scans: bilateral tumors with high FAZA uptake, representative for hypoxic tumors. Lower scans: non-
hypoxic tumor (left) with low FAZA uptake. High 18F-FAZA uptake was also seen in the urinary 
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RT;  = Combination (RT+). (A) T/B ratios (single values) of 18F-FAZA PET/CT (pre- or post-
treatment). Dotted line= cut-off for hypoxic tumors (T/B≥ 3.59). Hypoxic tumors are numbered. 
Colors refer to treatment response: red= radioresistant (RTG> 100%); green= radiosensitive (RTG< 
100%).  (B) Ratios of T/B after treatment to T/B before treatment (single values, mean, SD). (C) 
Transverse 18F-FAZA PET/CT slices at the level of the hind legs with a left subcutaneous tumor 
(orange). Mice in prone position. The clear hypoxic zone with high FAZA uptake that existed pre-
treatment, disappeared after irradiation. 
 
DISCUSSION 
This study investigated the predictive value of 18F-FAZA PET/CT for hypoxia-induced 
radioresistance in EAC and the radiosensitizing effect of nimorazole. 
We confirmed the existence of hypoxia-induced radioresistance and the radiosensitizing 
effect of nimorazole in the OACM5 1.C SC1 cell line in vitro as well as in vivo in EAC 
xenografts. We showed that a T/B of ≥ 3.59 on pre-treatment 18F-FAZA PET/CT predicts 
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that this cut-off also identifies tumors that could benefit from combination treatment with 
nimorazole.  
It is difficult to compare the cut-off value of 3.59 with other studies, because no consensus 
exists for quantifying 18F-FAZA uptake. Some studies quantify tracer uptake as percentage 
of the totally injected activity (%ID/g or SUV (standardized uptake values) if standardized 
to the animals’ weight). Because FAZA is excreted in urine and feces, individual tracer 
activity at the moment of the scan, i.d. 3 hours post-injection, varied substantially between 
animals. Therefore, like other studies [78, 124], we used tumor to background ratios, where 
tumor activity is compared to a reference non-hypoxic tissue. We calculated mean and 
maximum tumor uptakes and used lung or muscle as background tissue. We also calculated 
tumor uptake using the 40% isocontour VOI tool (available in Amide.exe 1.0.4), similar to 
Tran et al. [123]. The last method provided the strongest T/B parameter to predict treatment 
response and was chosen as predictive parameter for this model. Interestingly, the cut-off 
of 3.59 is in the range of the cut-off value proposed by Tran et al. [78]. They investigated 
18F-FAZA uptake in a rhabdomyosarcoma xenograft model and found that T/B > 2.72 
identifies highly hypoxic tumors which benefit from pre-treatment with nimorazole.  
As 18F-FAZA PET/CT has already been proven to be safe in the clinical setting and this 
study proved its predictive value in EAC xenografts, we believe it would now be interesting 
to analyze 18F-FAZA PET/CT in EAC patients. However, certain difficulties may arise. 
EAC tumors are preferentially localized at the distal esophagus [115]. Because FAZA is 
excreted biliary (after hepatic metabolization) and renally [62], there is a lot of background 
tracer activity in those regions, which could impede tumor visualization. We tested the 
feasibility of 18F-FAZA-PET/CT in a distal esophageal tumor mass in an additional mouse 
experiment. Tumor delineation was not possible due to intense liver tracer uptake combined 
with poor soft tissue resolution of the small animal CT. Nevertheless, we believe 
visualization in patients will be better because the higher soft tissue resolution on human 
CT scans. For esophageal squamous cell carcinomas, typically located in the thoracic part 
of the esophagus, this should not be a problem. 
The benefit of nimorazole was more evident in the in vitro experiments than in the xenograft 
model. Probably, the RT regimen itself had radiosensitizing effects. In vitro, single doses 
were used, where in vivo we used a hypofractionated schedule because a clinically relevant 
schedule was aimed at (23 x 1.8 Gy according to the recent CROSS trial [82]). Because 
copying the exact clinical regimen would be impracticable, we opted for a hypofractionated 
 
85 
schedule of 5 x 5 Gy. On the one hand, as was seen in vitro, higher irradiation doses cause 
less hypoxic radioresistance than smaller doses. On the other hand, fractionation is known 
to cause tumor cell reoxygenation between the doses and enhances RT efficacy as such 
[125, 126]. Indeed, post-treatment 18F-FAZA PET/CT showed a normalization of hypoxia 
status in 5/6 hypoxic tumors after RT alone or combined with nimorazole.  
Predicting treatment response in the clinical setting offers possibilities for individualized 
treatments. For example, if a tumor is predicted to show a good response, it is worth to 
administer neoadjuvant treatment before surgery. Meanwhile, if a tumor is predicted to be 
resistant to neoadjuvant treatment, it could be better to perform the surgical resection earlier 
or to modify the neoadjuvant treatment and decrease radioresistance, like modifications to 
the RT regimen itself (e.g. dose-painting [127]) or addition of a hypoxia modifier (e.g. 
nimorazole [128]). Still, tumor hypoxia is distributed heterogeneously in space and over 
time [6]. For sure, hypoxia distribution and status of the tumors will change during the 
neoadjuvant treatment. Repetitions of 18F-FAZA PET/CT during treatment are needed to 
reevaluate tumor’s hypoxia status and indications for radiosensitizers.  
 
CONCLUSION 
This study on esophageal adenocarcinoma showed that a T/B ≥ 3.59 on 18F-FAZA PET/CT 
is predictive for worse RT response. The benefit of nimorazole in hypoxic tumors seems 
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CHAPTER 6: HYPOXIA AS RESULT OF TUMOR 





 This chapter is based on the following article:  
Melsens E, Verberckmoes B, Rosseel N, Vanhove C, Descamps B, Pattyn P, Ceelen 
W. The VEGFR Inhibitor Cediranib Improves the Efficacy of Fractionated 




Background: Radiotherapy (RT) increases local tumor control in locally advanced rectal 
cancer, but complete histological response is seen in only a minority of cases. Anti-
angiogenic therapy has been proposed to improve RT efficacy by ‘normalizing’ the tumor 
microvasculature. Here, we examined whether Cediranib, a pan–VEGF receptor tyrosine 
In the previous chapters, we developed an EAC tumor model that was 
feasible for 18F-FAZA PET/CT imaging and that was used to answer the 
first research question ‘Can hypoxia imaging with 18F-FAZA PET/CT 
serve as a predictive biomarker and as a guidance for hypoxia targeting?’. 
We showed that tumor hypoxia imaging with 18F-FAZA PET/CT is a 
useful predictive biomarker for treatment response in an EAC model in 
mice. We further showed that targeting of hypoxia with nimorazole 
seemed to improve radiation response of hypoxic tumor (identified with 
18F-FAZA PET/CT). 
In this chapter, we investigated the second research question: ‘Can anti-
angiogenic therapy reduce hypoxia and enhance radiotherapy efficacy?’ 
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kinase inhibitor, improves microvascular function and tumor control in combination with 
RT in a mouse colorectal cancer (CRC) model.  
Methods: CRC xenografts (HT29) were grown subcutaneously in mice. Animals were 
treated for 5 consecutive days with vehicle, RT (1.8 Gy daily), cediranib (6mg/kg PO), or 
combined therapy (cediranib 2 hours prior to radiation). Tumor volume was measured with 
calipers. Vascular changes were analyzed by dynamic contrast enhanced-MRI, oxygenation 
and interstitial fluid pressure probes and histology. To investigate vascular changes more in 
detail, a second set of mice were fitted with titanium dorsal skinfold window chambers, 
wherein a HT29 tumor cell suspension was injected. In vivo fluorescence microscopy was 
performed before and after treatment (same treatment protocol).  
Results: IVM analyzes showed that VEGFR-inhibition with cediranib led to a 
‘normalization’ of the vessel wall, with decreased microvessel permeability (p< 0.0001), 
tortuosity (p< 0.01) and a trend to decreased vessel diameters. This seemed to lead to lower 
tumor hypoxia rates in the cediranib and combination groups compared to the control and 
RT groups. This led to an increased tumor control in the combination group compared to 
controls or monotherapy (p< 0.0001). 
Conclusions: The combination of RT with cediranib enhances tumor control in a CRC 
xenograft mouse model. Microvascular analyses suggest that cediranib leads to vascular 





Colorectal cancer (CRC) is the third most frequent cancer and the fourth most frequent 
cause of cancer related death worldwide [129]. Standard therapy consists of surgical 
resection with or without adjuvant chemotherapy or radiotherapy (RT). The addition of 
neoadjuvant RT has been shown to increase local tumor control and sphincter preservation 
in case of locally advanced rectal cancer (LARC), compared to surgery alone [130]. 
Nevertheless, this did not lead to a significant benefit in overall survival. Despite regimens 
combining RT with chemotherapy, complete histological response is seen in only a minority 
of cases and has been linked to patient’s prognosis. As such, there is a need to enhance the 
efficacy of RT. 
An important cause of radioresistance is related to the vascular tumor microenvironment 
[131]. Because tumor cells are highly proliferative, angiogenesis is stimulated to cope with 
the increased need for oxygen and nutrients. Tumor vessels are typically dilated, 
hyperpermeable and tortuous, and lead to an abnormal tumor microenvironment 
characterized by an increase in interstitial fluid pressure (IFP), hypoxia and acidosis, 
leading to chemo and radioresistance [8].  
The key pro-angiogenic factor in tumor angiogenesis is vascular endothelial growth factor 
(VEGF). The VEGF family consist of 5 signal proteins, of which VEGF-A is the most 
important for angiogenesis. After binding with one of the three tyrosine kinase receptors, 
angiogenesis (VEGFR-1 and -2) or lymphangiogenesis (VEGFR-3) is stimulated. 
Activation of the VEGF signaling pathway has stimulating effects on endothelial cells 
(migration, survival and proliferation) and increases vascular permeability [37]. As such, 
inhibition of the VEGF signaling pathway is a promising way to rebalance tumor 
angiogenesis and ‘normalize’ the hostile tumor microenvironment, making tumors more 
acceptable for chemo and RT. 
In this study, cediranib (AZD2171) was investigated, an orally active, highly potent tyrosine 
kinase inhibitor that acts on all 3 VEGF-receptors. Cediranib may lead to a more 
pronounced anti-angiogenic effect than for instance bevacizumab (Avastin), which 
specifically binds VEGF-A. Previous in vitro and in vivo experiments in colon, head and 
neck and non-small cell lung cancer models, demonstrated the inhibitory effects of 
cediranib monotherapy on tumor angiogenesis and tumor growth [132-135]. Clinical trials 
showed promising results for cediranib combined with chemotherapy in patients with 
metastatic CRC (mCRC), but results for progression free survival (PFS) and overall survival 
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(OS) were rather disappointing when compared to chemotherapy with bevacizumab 
(HORIZON trials) [136-138]. Yet, combination of cediranib and RT in CRC has not been 
studied except for one [139]. Williams et al. performed a mouse xenograft study (colon 
tumors (LoVo)) and illustrated a significant higher tumor growth inhibition with cediranib 
and RT compared to RT alone. Unfortunately, underlying anti- angiogenic effects were only 
studied in lung carcinoma xenografts.  
Here we investigated the effects of combination treatment of fractionated RT and cediranib 
on tumor growth and tumor microvessels and microenvironment in a CRC xenograft mouse 
model. Understanding the potential enhancement of RT efficacy in CRC through VEGF 
signaling inhibition with cediranib is important for future clinical studies and could change 
neoadjuvant therapy regimens.  
 
MATERIALS AND METHODS 
TUMOR MODEL 
The human colon cancer cell line HT29 was kindly provided by the Department of 
Experimental Cancer Research, Ghent University, Belgium. Cells were cultured at 37°C in 
5% CO2 humidified atmosphere in McCoy’s Medium (Life Technologies, Ghent, Belgium), 
supplemented with 10% fetal bovine serum, penicillin-streptomycin and fungizone. Cells 
were authenticated by STR DNA profiling. 
Animal experiments were approved by the Animal Ethical Committee of the Ghent 
University, Belgium (approval code 14/02). Athymic mice (Foxn1nu male) were obtained 
from ENVIGO, the Netherlands, and housed with access to tap water and standard pellet 
food. At 8 weeks of age, tumors were induced under general anesthesia (Isoflurane, 5% 
induction, 2% maintenance) at two locations: subcutaneously (SC) or in dorsal skinfold 
window chambers (DSWC). At the end of the experiments, or when humane endpoints were 
reached, mice were euthanized by cervical dislocation. 
 
DSWC 
Under general anesthesia (Isoflurane) and analgesia (Ketoprofen, 5mg/kg, SC) DSWC were 
implanted on a heating pad. First, the posterior part of the titanium frame was sutured on 
the back of the mouse. Then, a circular skin flap (dermis and subcutis) was unilaterally 
removed and the anterior part of the frame was attached. The open wound was humidified 
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(saline water) and closed with a cover glass. After initial in vivo microscopy (day 0), tumor 
cells (1x106 HT29 cells suspended in 20µL Matrigel® (Corning BV, Amsterdam, the 
Netherlands)) were injected into the chamber (Fig 1.A). 
 
SC XENOGRAFTS 
1.5x106 HT29 cells suspended in 40 µL Matrigel were injected (30G needle) bilaterally SC 
in the hind legs of the animal. One nodule was used for DCE-MRI imaging and 
immunohistochemistry, the other for probe measurements. Pimonidazole hydrochloride 
(Hypoxyprobe®, Burlington, MA, USA) (60mg/kg, IP), a hypoxia marker, and Hoechst®-
33342 (Sigma- Aldrich, Diegem, België) (15mg/kg, IV), used as perfusion marker, were 
administered in the tail vein 2 hours and 1 minute before sacrifice, respectively. Tumor 
dimensions were measured weekly with calipers and daily during therapy. Tumor volumes 
(V) were calculated as V = (length * width) 3/2 * π/6 (Fig 1.B). 
 
 
FIGURE 1: Experiment timeline. (A) Induction of HT29 tumors in DSWC in mice at day 0. Four 
treatment groups. Daily treatment from day 3 to 7. IVM before and after treatment. Euthanasia after 
last measurement. (B) Induction of HT29 tumors subcutaneous in the hind legs of mice at day 0. Four 
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treatment groups. Daily treatment from day 17 to 21. DCE-MRI and pO2 measurements before and 
after treatment. IFP measurement after treatment. Euthanasia after last measurement. 
 
EXPERIMENTAL THERAPY 
Treatment was started at day 3 (DSWC) and day 17 (SC xenograft) after tumor induction 
and given for 5 consecutive days (Fig 1). Mice were divided into 4 groups. A control group 
received 150 µl of 1% Polysorbate 80 orally once daily. A second group received cediranib 
(Recentin™, AZD2171, Astra Zeneca, Brussels, Belgium) (6mg/kg/day, orally). The third 
group received RT at a dose of 1.8 Gy/day, while the fourth group was treated with 
combined cediranib and RT with cediranib administered 2 hours before RT. Cediranib was 
dissolved in 1% polysorbate 80 (tween 80) with deionised water and sterilised by 
autoclaving.  
RT was applied using the small animal radiation research platform (SARRP, XStrahl LTD, 
Surrey, UK). Mice were anesthetized and positioned on the bed of the SARRP. Guided by 
lasers, the bed was moved to position tumors/DSWC at the isocenter of the beam. A pair of 
parallel- opposed (anterior- posterior) radiation beams of 10x10mm2 were used. The 
voltage of the X-ray source was fixed at 220 kV with a tube current of 13 mA, emitted from 
the 3 mm focal spot and filtered by a copper filter of 0.15 mm. Doses of 1.8Gy were 
delivered daily for 5 consecutive days. 
 
EXPERIMENTAL MEASUREMENTS 
IN VIVO MICROSCOPY (IVM) 
Fluorescence IVM was performed on day 0 and day 8 after tumor implantation. Mice were 
anesthetized (Isoflurane) and positioned on a heating pad. A catheter (30G) was placed in 
the tail vein for administration of fluorescent tracer, the cover slip was removed from the 
chamber and the animal was placed under the microscope (modified BX51W, Olympus, 
Aartselaar, Belgium). In case of dehydration of the chamber, saline water was locally 
applied. Mice received a bolus of 30 µL of IV Fluorescein isothiocyanate (FITC)-dextran 
(MW 40 kDa) in NaCl 0.9% (20 mg/mL). At the same time, registration of images (dynamic 
and static) started (magnification 100x). Fluorescence microscopy was performed using a 
HBO 50W mercury lamp (Osram, Zaventem, Belgium) and a FITC filter set (excitation 
filter 460-490nm). Images were saved on a computer using a high sensitivity digital camera 
(model C8484-05, Hamamatsu, Louvain-la-Neuve, Belgium). To analyze vascular 
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permeability, one location was imaged over 15 minutes at 4 time intervals (0’–0’30”; 1’30”-
2’00”; 4’30”-5’00”; 15’00”-15’30”). Two other locations were imaged (each 30”) at the 
right upper and left lower quadrants of the tumor.  
 
MICROCIRCULATORY ANALYSIS 
Off-line analysis was performed with the CapImage software package (H Zeintl 
Engineering, Heidelberg, Germany) and included the calculation of: number of 
microvessels per area (N/A, count/mm2), microvessel diameter (d, µm) and centerline red 
blood cell velocity (VRBC, mm/s). Microvessel diameter and VRBC were analyzed for 10 
randomly chosen microvessels of interest crossing a vertical line in the middle of the image 
at 3 locations, as described previously [140]. Considering the parabolic velocity profile of 
blood in microvessels, the volumetric blood flow (VQ) was calculated by VQ = π * (d/2)2 
* VRBC/K, where K (=1.3) represents the Baker/Wayland factor [141]. Post- to pre-treatment 
rates were calculated and compared between groups. Additionally, microvessel tortuosity 
(T) and mean interstitial fluorescence intensity (MFIinter) were calculated with the NIH 
ImageJ software (Version 1.48, available from https://imagej.nih.gov/ij/). T was calculated 
from 6 randomly chosen microvessels at 3 locations and was defined as T (%) = (1-
SP/L)*100, where SP represents the shortest distance between 2 branching points (i.e. the 
distance between two branching points along a straight line) and L represents the segment 
length (i.e. the distance between the branching points along the vessel), according to Norrby 
et al [142]. MFIinter was calculated from 10 randomly chosen regions-of-interest (ROIs) that 
were drawn in the interstitial space at 3 locations. Using the TimeSeriesAnalyzer plugin, 
the mean fluorescence intensity (=mean grey value) was calculated as a function of time 
and curve analysis was performed. 
  
DYNAMIC CONTRAST-ENHANCED MRI (DCE-MRI) 
Animals were scanned before and after treatment (day 13 and 24) on a 7 tesla magnet 
(PharmaScan 70/16, Bruker, Ettlingen, Germany) with a mouse body volume coil. Mice 
were anesthetized with isoflurane (5% induction, 1.5% maintenance, 0.3L/min) and 
warmed with a water-based heating blanket. Respiration was monitored using a respiration 
pad underneath the mouse. Anatomical information was obtained with a T2-weighted 
sequence (TurboRARE) with the following parameters: TR 3661ms, TE 37.1ms, in-plane 
resolution 109 µm, 30 contiguous transverse sections of 600 µm, and acquisition time 9’1”. 
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Pre- and post-contrast injection, T1-weighted images were obtained with a RARE sequence 
with parameters TR 1464 ms, TE 9.1 ms, in-plane resolution 117 µm, 30 contiguous 
sections of 600 µm, and acquisition time 4’17”. DCE-MRI images were acquired for a 
single slice using a FLASH sequence with the following parameters: TR 12 ms, TE 3.4 ms, 
in-plane resolution 268 µm, 550 repetitions, temporal resolution 1.344 seconds, and 
acquisition time 12’19”. An oblique slice was chosen such that both tumors were imaged. 
One minute after the start of acquisition, the gadolinium-based contrast agent Vistarem® 
(50 mmol/kg IV, Guerbet, Villepinte, France) was injected. Total acquisition time per 
session was 35 minutes. Dynamic time series were analyzed with MIStar version 3.2.62.03 
(Apollo MIT, Melbourne, Australia) using curve analysis. The following parameters were 
calculated: area under the curve (AUC), maximum uptake slope (MUS), maximum washout 
slope (MWS), area under the curve until time to peak (rAUC ttp). ROIs were manually 
drawn around tumors (ROI) and mean values were calculated. 
 
TISSUE OXYGENATION AND INTERSTITIAL FLUID PRESSURE 
At day 14 and 25, tumor oxygenation was measured with a fluorescence based fiberoptic 
probe (OxyLite System, Oxford, Optronix, Oxford, UK), as described previously [143]. 
Mice were anesthetized and placed on a heating pad. The probe was inserted in the tumor 
through pre-tunneled tracks (18G IV catheter BD) and fixed to a micromanipulator (model 
MN151, Narishige International Ltd, London, UK). Tissue pO2 was sampled every spatial 
step of 200 µm for 3 minutes, up to 25 measurements. Data was acquired with a 
Powerlab/8sp (ADInstruments, Oxford, UK) and plotted using Chart 5.0 software. The 
hypoxic fraction was calculated as the percentage of measurements with a pO2 < 5 mmHg 
(HP5 (%)). 
Interstitial fluid pressure (IFP) was measured at day 25, with a Samba Preclin probe (Samba 
Sensors, Bioseb, Vitrolles, France) according to the method reported by Ozerdem [144]. 
The probe was calibrated in air, and inserted in a perforated catheter (22G IV Catheter 
Insyte-W, Becton Dickinson) filled with gel (Duratears, Alcon). The system was placed in 
the tumor center through a pre-tunneled track. After acquiring a stable curve, tumor IFP 
(relative to the atmosphere, mmHg) was recorded during 5 minutes and mean pressures 






Tumors were excised and divided in half. One part was impregnated with formaldehyde 
4%, embedded in paraffin and cut in 5 µm thick sections using a microtome (Microm 
HM355S, Thermo Scientific, Rockford, IL, USA). Tumor regions were identified and 
general aspects (necrosis, cell density…) were evaluated on H&E stained slides with a light 
microscope (ColorView I, BX43F, Olympus, Tokyo, Japan). Standard Ki67 staining was 
carried (primary rabbit monoclonal anti-human/rat/mouse Ab Anti-Ki67 [SP6] (ab16667) 
and HRP anti-rabbit secondary Ab, both DAKO K4011). Proliferation indices (fraction of 
Ki67+ cells/total cells) were calculated by hotspot analysis (6 per slide, magnification 400x) 
with ImmunoRatio (Institute of Biomedical Technology, University of Tampere, Finland).  
Additionally, exogenous administered pimonidazole was stained. Sections were 
deparaffinized in xylene and rehydrated in ethanol. Antigens were unmasked with citrate 
buffer (pH=6, 20 min, 95 °C). Endogenous peroxidase was blocked with 3% H2O2 in PBS 
(10 min at RT) and mouse IgG with the Mouse on Mouse (M.O.M.) basic kit (1hour at RT, 
ref. BMK-2202 Vector Lab.). Then, the primary antibody was applied, Hypoxyprobe anti-
pimonidazole mouse IgG1 monoclonal Ab (HP1-100Kit) for 1h at room temperature 
followed by the secondary antibody from LSAB+ System-AP kit (DAKO K0675(11)) 
according to manufacturer’s protocol. Hypoxic fraction (%, pimonidazole+ area/total tumor 
area) was calculated with ImageJ (NIH).  
Furthermore, staining for endothelial cells (CD105, endoglin) was performed. 
Deparaffination, rehydration, unmasking and blocking (endogenous peroxidase) were 
performed as described above. Then, proteins were blocked with blocking buffer (from 
Vectastain kit, AP Goat IgG AK-5005) for 30 min at 37°C. Primary antibody for endoglin 
(monoclonal goat anti-mouse, CD105 R&D system AF1320) was applied at 1/50 in TBS 
and blocking buffer, according to the manufacturer’s protocol. Secondary antibody was 
applied from Vectastain kit (AP Goat IgG AK- 5005) for 30 min and streptavidin-AP was 
applied for 30 min. Detection was performed with fuchsine chromogen for 1min at room 
temperature (RT) and counterstaining with hematoxylin. Mean vessel density (MVD, 
number of vessels per area (mm2)) was calculated by hotspot analysis (up to 6 hotspots per 
slide, magnification 200x) with ImageJ (NIH). 
In addition, TUNEL staining was performed to detect apoptosis. Deparaffination and 
rehydration were performed as described above. Antigens were unmasked with citrate 
buffer (pH=6, 20min, 95°C, + 0.1% Tween 20). Then, the In-Situ Cell Death Detection Kit, 
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Fluorescein, (Roche 11684795910) was used according to manufacturer’s protocol to 
perform the TUNEL reaction. Counterstaining was performed with Vectashield medium 
with DAPI. Sections were analyzed with the fluorescence microscope (Zeiss Axiovert 
200M, software Axiovision 4.1), 6 random fields with magnification were selected and the 
percentage of double stained cells (TUNEL+ and DAPI+) on all DAPI+ cells was 
calculated. 
The other part of the tumor was snap frozen (-80°C). Ten µm cryostat sections were 
prepared and evaluated for Hoechst staining with fluorescence microscopy. Whole tumor 
sections were scanned at magnification 400x and the perfusion index (Fraction of perfused 
area/total tumor area) was calculated using ImageJ (NIH). 
 
STATISTICAL ANALYSIS 
Statistical analysis was performed with GraphPad Prism 6 (Graphpad Software, Inc.: La 
Jolla, CA, USA). Data were analyzed with non-parametric tests (Kruskal-Wallis and Mann 
Whitney U test) and summarized as medians. Tumor growth and microvessel permeability 
were determined by non-linear regression analysis (exponential growth and one-phase 
association). Results were considered statistically significant when the probability of a type 
I error was ≤ 0.05.  
 
RESULTS 
EFFECT OF CEDIRANIB AND RT ON TUMOR GROWTH AND 
PROLIFERATION 
Tumor growth was calculated from the measurements of SC tumors. Addition of cediranib 
to RT led to a significantly increased growth delay compared to RT alone with an increase 
in tumor doubling time from 13.16 days with RT alone to 27.13 days with combination 
treatment (p<0.0001, Fig. 2A). In addition, cediranib monotherapy and RT monotherapy 
led to a similar growth inhibition compared to controls. 
Addition of cediranib to RT led to moderately higher apoptotic rates compared to RT alone 
(Fig 2.B, D above). Alternatively, cediranib and RT led to somewhat higher proliferation 
rates, while the combined treatment led to significantly higher proliferation rate compared 
to controls (p< 0.05) (Fig 2.C, D under). The control group had the densest tumors, with the 
least necrotic areas. All treatment groups showed diffuse areas with less tumor cell density, 
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probably due to treatment induced cell death followed by cell loss. The combination 
treatment group had the least cell-dense tumors. 
 
 
FIGURE 2: Tumor growth. (A) Relative tumor growth of subcutaneous HT29 tumors. Exponential 
growth curves, mean, standard deviation. (B) Apoptotic rates calculated from TUNEL staining. 
Percentage of TUNEL positive stained cells on the total cell count. p= 0.5208, single values, median. 
(C) Proliferation rates calculated from Ki67 staining. Percentage of Ki67 positive stained cells on the 
total cell count. p= 0.0772, single values, median. (D) Representative images of TUNEL staining 
(above) and Ki67 staining (under) of each treatment group. Above: green= TUNEL positive cells, 
blue= DAPI positive cells. Magnification 200x, scale bar 100µm. Compared to controls, treatment 
groups show more apoptosis. Under: brown= Ki67 positive cells. Magnification 400x, scale bar 50µm. 
No difference in Ki67 staining between the groups is seen at first sight. After quantification, the 




EFFECT OF CEDIRANIB AND RT ON TUMOR VASCULATURE 
Figure 3 shows representative pictures of a DSWC of each treatment group, illustrating that 
the cediranib and combination groups (Fig 3.C-D) displayed more linear and less dilated 
vessels than the control and RT groups (Fig 3.A-B), whereas microvessel density did not 
differ greatly between the groups. 
 
 
FIGURE 3: In vivo microscopy. (A-D) DSWC images after 5 days of treatment. Representative 
images of each treatment group. Magnification 100x, scale bar 100µm. Vessels of the control and 
radiotherapy group appear to be more tumoral (more tortuous, more dilated) than those of the groups 
treated with cediranib.  
 
Quantification of these DSWC with the additional histologic and DCE-MRI analyses of the 
SC xenografts led to the following results on tumor vasculature. Cediranib and RT did not 
lead to a change in vessel density calculated from the DSWC (N/A, Fig 4.A) or calculated 
from the endoglin stained sections in the SC xenograft group (MVD, Fig 4.B, E). Further, 
no difference was seen between the groups in volumetric blood flow (VQ, Fig 4.C) or tumor 
perfusion (Hoechst, Fig 4.D). Curve analysis of DCE-MRI did not show any differences 
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between the groups for the amount of leaked contrast (AUC, rAUC ttp), the velocity of 
leakage (MUS) or the velocity of washout of contrast (MWS) (Fig 5. A-D).  
 
 
FIGURE 4: Tumor vessel density and tumor perfusion. (A) Number of vessels per area (N/A) 
calculated from IVM images. p= 0.4563, post- to pre-treatment rate, single values, median. (B) Mean 
vessel density (MVD) calculated from endoglin stained sections of SC tumors. Number of vessels per 
area (mm^2). p= 0.4320, single values, median. (C) Volumetric blood flow (VQ) calculated from 
IVM images. p= 0.6251, post- to pre-treatment rate, single values, median. (D) Perfusion rate 
calculated from Hoechst stained sections of SC tumors. Percentage of Hoechst positive stained area 
on total tumor area. p= 0.0637, single values, median. (E) Representative images of endoglin staining 
of each treatment group. Pink= endoglin. Blue= cell nuclei. Magnification 200x, scale bar 100µm. No 








FIGURE 5: DCE-MRI analyses. (A) Area under the curve. p= 0.6804, post- to pre-treatment rate, 
single values, median. (B) Area under the curve until time to peak. p= 0.5190, post- to pre-treatment 
rate, single values, median. (C) Maximum uptake slope. p= 0.3119, post- to pre-treatment rate, single 
values, median. (D) Maximum washout slope. p= 0.1180, post- to pre-treatment rate, single values, 
median. 
 
However, cediranib led to a significant decrease in vessel permeability compared to the 
control or RT group (p<0.0001) calculated from the DSWC imaging data (MFIinter, Fig 6). 
As can be seen in Fig 6, there was a relatively fast accumulation of contrast agent (CA) in 
the interstitial space during the first time interval (0” – 30”), reaching a plateau phase at the 
second time interval (1’30”-2’00”) that persisted at the 2 latest time points (4’30” and 
15’00”). The washout phase was not observed.  
Moreover, cediranib led to a significant decrease in microvessel tortuosity (T, Fig 7.A) (p< 
0.01) and cediranib inhibited, although moderately, dilatation of microvessels compared to 





FIGURE 6: Tumor vessel permeability. Mean interstitial fluorescence intensity at 4 time intervals: 




FIGURE 7: Tumor vessel tortuosity and diameter. (A) Tumor vessel tortuosity calculated from 
IVM images. p< 0.05, post- to pre-treatment rate, single values, median. (B) Tumor vessel diameter 




EFFECT OF CEDIRANIB AND RT ON TUMOR 
MICROENVIRONMENT 
Lower tumor hypoxia rates were observed in the cediranib and combination groups 
compared to the control and RT groups (HP5%, Fig 8.A). Furthermore, addition of 
cediranib to RT led to a significant decrease in tumor hypoxia (p< 0.05) (pimonidazole, Fig 
8.B). 
Surprisingly, cediranib led to a significant increase in IFP compared to RT (p< 0.05) while 



















FIGURE 8: Tumor microenvironment. (A) Tumor hypoxia calculated from OxyLite probe 
measurements of SC tumors. Hypoxic fraction (% < 5 mmHg pO2). p= 0.2418, difference after- 
before, single values, median. (B) Tumor hypoxia calculated from pimonidazole stained sections of 
SC tumors. Percentage of hypoxic area on total tumor area. p< 0.05, single values, median. (C) Tumor 
interstitial fluid pressure calculated from Samba Preclin probe measurements of SC tumors. p< 0.05, 






This study investigated the effect of combining fractionated RT with cediranib, a pan-
VEGF-receptor tyrosine kinase inhibitor, in a human CRC mouse model. For the first time, 
the underlying microvascular changes of this combined treatment in CRC were evaluated 
in vivo. 
Cediranib was shown to successfully enhance tumor growth inhibition of RT (p<0.0001) 
and to increase, although moderately, tumor cell apoptosis. Only one previous study was 
performed on the combined effect of RT and cediranib in CRC [139]. Mice with SC 
xenografts (human LoVo cell line) were treated with RT (2Gy/ day, for 5 days) and 
cediranib (6mg/kg, continued for 28 days in total).  Similar to our study, improved tumor 
growth inhibition was seen during combined treatment and continued cediranib treatment. 
Unfortunately, underlying microvascular changes were not investigated.  
One proposed and frequently debated mechanism is the one of microvessel normalization 
[41]. Inhibition of VEGF-signaling may induce ‘normalization’ of tumor microvessels, 
which could lead to better perfusion and oxygenation of tumor tissue. Because oxygen is 
important for the generation of free radicals and DNA damage, oxygenated tumor tissue 
reacts 2- 3 times better to RT than hypoxic tumor tissue [25, 145]. As such, microvessel 
normalization might sensitize tumors for RT. This study focused on the in vivo imaging of 
these vascular changes and normalization. First, microvessels were shown to be 
significantly less tortuous (p=0.0066) after cediranib treatment. Second, microvessels had 
moderately smaller diameters after cediranib treatment and third, cediranib decreased vessel 
permeability (p<0.0001). As previously proposed in other xenograft studies [134, 139, 146, 
147], this suggests cediranib induces clear changes in microvessel structure and leads to a 
normalization of the microvessel wall. For the first time, these changes were imaged in vivo 
with DSWC in CRC.  
Single high dose RT (10-30 Gy) is known to have anti- angiogenic effects with 
disappearance of small tumor vessels in the acute phase and stimulation of tumor 
angiogenesis at long-term (after 14 days) [148]. Yet, nothing is known about the effect of 
fractionated RT and cediranib on tumor microvasculature in CRC. Our results suggest that 
fractionated radiation (5 x 1.8 Gy) has no immediate anti-angiogenic effects like single high 
dose RT. This is illustrated in figure 3 where the control and RT treated tumors clearly show 
tumor vessel structures, in contrast to the cediranib and combination treated group, that 
appear to have a more normal vessel structure. The underlying pathways were not 
 
106 
investigated but are suggested to be divergent. VEGF-inhibition with cediranib inhibited 
these pro-angiogenic effects only partially. A new study will be started in the near future to 
investigate microvasculature after single high dose RT versus fractionated RT. 
These observed microvascular changes are thought to lead to changes in tumor 
microenvironment. Indeed, cediranib decreased tumor hypoxia, which explains the lower 
radioresistance and the enhanced tumor growth delay. The fact that addition of cediranib to 
RT led to a decrease in tumor hypoxia compared to RT alone could be due to a better 
response to RT (higher apoptotic rate in combination treated group) followed by a decrease 
in oxygen consumption. The increased proliferation rates of tumors in the combined 
treatment group could be due to the same mechanism of a proportional increased 
proliferative potential of tumor cells that survived treatment. The effect of this proportional 
increased proliferation remains to be investigated in future studies with longer follow-up. 
With respect to the interstitial fluid pressure, it is known that most solid tumors show an 
increased IFP (normal tissue: IFP= -1 to -3mm Hg [149, 150]) due to vessel abnormalities, 
fibrosis and contraction of the interstitial matrix [151]. Certain VEGF signaling pathway 
inhibitors, such as bevacizumab, lead to normalization of this raised IFP [152]. This was 
the first study to investigate the effect of cediranib on IFP. Surprisingly, cediranib led to a 
significant increase in IFP compared to RT. This might be due to the inhibitory effect of 
cediranib on lymphangiogenesis through VEGFR-3 inhibition. Indeed, it has been shown 
previously that stimulation of VEGFR-3 through VEGF-C decreases IFP [153]. 
Remarkably, 3 days after cessation of therapy, the reduction in vessel permeability was not 
visible anymore (DCE-MRI). A similar study, where DCE-MRI was performed 
immediately after administration of cediranib (2h), could demonstrate a reduction of 70% 
in permeability surface area product per unit volume of tissue (parameter for permeability) 
[147]. These findings support the fact that cediranib leads to rapid changes in 
microvasculature, described as a ‘window of normalization’ [8], which disappear after 
cessation of therapy. These fast changes underscore the importance of treatment timing and 
in vivo measurements of treatment effects. 
This study emphasizes the potential benefits of further investigating the role of cediranib in 
a neoadjuvant setting in locally advanced rectal cancer, combined with RT. Several phase 
II trials with bevacizumab and neoadjuvant radiochemotherapy have been performed in 
LARC [154, 155]. So far, results were not very promising with increased toxicities and 
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increased post- operative morbidity as major obstacles. Whether cediranib will do better, is 
to be investigated.  
 
CONCLUSION 
We showed that the combination of fractionated RT with the VEGFR- inhibitor cediranib 
enhances tumor control in a colorectal xenograft model. In addition, the imaged structural 
and functional vascular changes suggest that cediranib has a stabilizing effect on the vessel 






























CHAPTER 7: GENERAL DISCUSSION AND 
CONCLUSION 
Our objective was to study hypoxia in solid tumors and use it as a biomarker and target for 
individualized therapy.  
 
We started by describing the development of an EAC tumor model in chapter 3. Two 
generally available EAC cell lines were used, OE33 and OACM5 1.C and injected at an 
ectopic (subcutaneous, hind legs) or orthotopic site (distal esophageal wall through midline 
laparotomy). We also evaluated different in vitro functional cell line characteristics such as 
invasiveness or cell-cell adherence. We could conclude that the OE33 cell line has high 
subcutaneous and orthotopic tumor take rates, but that tumors grew extremely slow. Further, 
the OACM5 1.C cell line was not appropriate for tumor development in our tumor model. 
However, we succeeded to develop a daughter cell line of OACM5 1.C through an in vivo 
selection technique, that was named OACM5 1.C SC1, which had improved tumor take 
rates and faster growing tumors. Taken these results together, we had a reliable orthotopic 
and subcutaneous EAC tumor model to perform further preclinical research on.  
The use of a xenograft model could be a point of criticism. This choice was based on a 
careful study of literature on esophageal carcinoma tumor models and after weighing pros 
and cons. A diversity of esophageal tumor models in a diversity of laboratory animals (rat, 
mouse, rabbit…) exist. The number of ESCC models overshadows the limited number of 
EAC models and no ideal EAC model has been developed yet [88, 156].  
On the one hand, a syngeneic EAC model could be used. These use immunocompetent 
animals and might more closely mimic carcinogenesis with its tumor-host immune 
interactions. With respect to EAC, no syngeneic cell line is available for laboratory animals, 
but a transgenic model is available in mice (GEMM genetically engineered mouse model 
[107]) and different reflux models [157, 158] and carcinogen or diet-induced models (e.g. 
caustic agents to cause inflammation of the esophagus) have been described. Disadvantages 
of these syngeneic models are that tumor development is unpredictable and seen in a late 
stage (time-consuming), and that no human tissues are investigated which can impede 
translation of the results to the clinical setting.  
On the other hand, xenograft models can be used where human cancer material is 
injected/implanted in immunodeficient animals (orthotopic or ectopic). More and more 
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interest is growing for patient derived xenografts (PDX), because tumor heterogeneity is 
better preserved and because they retain the structure and stromal components of the 
original tumor better compared to continuous human cancer cell lines [159]. Xenograft 
models are easy and the timing of tumor development can be approximately predicted. The 
major disadvantage is the use of immunodeficient animals with loss of tumor-host immune 
interactions.  
Taking into account all these aspects, we can support our choice to use a xenograft setting, 
where tumor development is consistent and can be more or less predicted.  
 
The next step was to test the feasibility of the hypoxia tracer 18F-FAZA in both tumor 
models, which was described in chapter 4. We encountered a problem of diffuse background 
activity in the liver and intestines which compromised accurate visualization of tumors in 
those regions (EAC at the distal site of the esophagus and gastro-esophageal junction). 
Background activity was also seen in the urinary bladder and gall bladder, but this was of 
lesser importance for our model. As was already mentioned previously, this is due to the 
tracer characteristics. 18F-FAZA is metabolized hepatically and excreted via the intestines 
and kidneys [62]. One could question why not switch to another tracer. Table 1 gives an 
overview of the principal radiopharmaceuticals applied in hypoxia PET imaging with its 
applications, advantages and disadvantages. As can be seen, a range of tracers has been 
developed in the search for the most specific hypoxia tracer with the highest tumor-to-
background rates. Four big families, based on 4 uptake mechanisms can be identified. The 
first family of tracers is 18F-FDG, where uptake is based on the Pasteur effect, with low 
hypoxia specificity. The second family are the nitroimidazoles which were discussed in the 
introduction of this thesis. These have been studied extensively and already reached clinical 
evidence. However, these face the problem of having to cross the phospholipid bilayer and 
at the same time the need to be hydrophilic, as to rapidly clear from background tissues. 
The third family are the ones based on reduction of Cu-ATSM, but some doubt exists for 
the hypoxia specificity [52]. And as last, the recognizers of CA9, a transmembrane protein 
in hypoxic conditions, which have not been studied much, but seem promising because no 
crossing of the phospholipid bilayer is needed. In this field of hypoxia tracers, FAZA is the 
second most studied one, after FMISO, and has proven to be superior to FMISO concerning 
tumor-to-background rates. Taken together this information, we believe FAZA is one of the 
leading contenders in reaching a clinical applicability for hypoxia imaging and believe 
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research should continue to confirm this. We expect that the delineation of distal esophageal 
tumors would be easier in the clinical setting than in mice because of the larger structures 
and better soft tissue resolution on clinical applications. Therefore, we continued in the 
following chapter with the evaluation of 18F-FAZA as a predictor for radiation response in 






TABLE 1: Principal radiopharmaceuticals applied in PET imaging of tumor hypoxia. Adapted 








In chapter 5 we used hypoxia as a biomarker and target for individualized treatment in EAC. 
By using 18F-FAZA PET/CT we evaluated the effect of hypoxia on radiation response in a 
mouse model with subcutaneous human EAC tumors. In a subset of animals, hypoxia 
imaging was performed also after treatment to evaluate the influence of treatment on 
hypoxia status. Further, we evaluated if hypoxic radioresistance could be decreased by 
pretreatment with the radiosensitizer nimorazole. We found that tumors with high 18F-
FAZA activity, were less inhibited by radiotherapy than tumors with less 18F-FAZA activity 
with respect to tumor growth. ROC analysis showed that a cut-off of 3.59 for tumor to 
background ratio could predict treatment response with good sensitivity (92.3%) and 
specificity (71.4%). We further showed on histology of the xenografts and with an in vitro 
cell viability assay (MTS) that hypoxia indeed caused radioresistance. Hereby we 
confirmed that hypoxia is a negative predictive factor in our xenograft model and that 
pretreatment 18F-FAZA PET/CT could identify tumors that will react worse to radiotherapy.  
In our model 18F-FAZA activity in the tumor was quantified as the ratio of mean tumor 
uptake to mean background uptake. Mean tumor uptake was calculated in the >40% 
isocontour volume according to Tran et al [123]. Mean background uptake was the mean 
18F-FAZA activity in a sphere with radius 1.5 mm in the foreleg muscle. This parameter 
was used because it delivered the most accurate cut-off to predict treatment response. Other 
research groups describe the use of maximum tumor uptakes [110] or mean tumor uptake 
of the whole tumor [160] and lung [62], pelvic muscle [160] or blood (heart [66])… as 
background tissues. The cut-off value and the T/B parameter that were used our study, were 
valuable in the xenograft subcutaneous model, but will need to be revised when translating 
it to the clinical setting where tumor growth is more variable, and neoadjuvant treatment 
differs. With respect to the quantification method of 18F-FAZA, it is not known which 
parameter is the most valuable. Most clinical studies use their own quantification method, 
but almost always reflect the most hypoxic areas in the tumor by using SUVmax or a kind of 
> x% isocontour method, and mostly compare this to a reference tissue (muscle, spleen…) 
[161-163]. A future clinical study should determine a spectrum of different parameters, and 
determine the most valuable one. Further, to target hypoxia based on 18F-FAZA PET/CT 
scan, the method of modification will influence the quantification method of 18F-FAZA. For 
dose-painting, a 3D-map of 18F-FAZA uptake is needed, and repeated 18F-FAZA scans are 
needed to offer an up-to-date identification of high hypoxic areas. For radiosensitizers such 
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as nimorazole, a cut-off can be more valuable than a 3D distribution map, to know if the 
modifier will be worth it or not.  
With respect to nimorazole, we found a clear in vitro evidence of radiosensitization under 
hypoxic conditions, but nimorazole was not able to fully revert the resistance. This is in line 
with other preclinical studies where a sensitizer enhancement ratio of about 1.4 is reported 
with single dose irradiation [164, 165], which is indeed smaller than the oxygen 
enhancement ratio of 2 - 3 that is usually referred to [24, 25]. Further, the benefit of 
nimorazole was less obvious in the xenografts. When evaluating all xenografts, no benefit 
is seen, but when evaluating only hypoxic tumors (based on 18F-FAZA) or hypoxic tumor 
areas (based on pimonidazole staining), there seems to be a trend of radiosensitization by 
nimorazole. This less pronounced effect could be due to the different radiation schedule that 
was used in vitro (single dose irradiation) and in vivo (hypofractionated). Indeed, a 
reduction in sensitizer enhancement ratio from 1.4 to 1.3 when combined with fractionated 
irradiation instead of single dose irradiation has been reported [165]. The Danish Head and 
Neck Cancer group (DAHANCA) performed substantial research on combination treatment 
of nimorazole with radiotherapy in patients with head and neck carcinomas (DAHANCA 
trials). Nimorazole was proven to enhance loco-regional control in HNSCC with a 
fractionated RT regimen (62- 68 Gy, 2 Gy per fraction) [35] and is part of daily practice in 
Denmark. In our EAC tumor model, nimorazole does not seem to be the ideal radiosensitizer 
to cope with hypoxic radioresistance. It remains to be investigated whether nimorazole has 
a sensitizing effect in the clinical setting, where a fully fractionated schedule is used. Such 
clinical study has to include hypoxia detection methods to identify patient that could benefit 
from nimorazole, because nimorazole has no effect in normoxic conditions.  
 
In the previous chapter, we investigated the effect of hypoxia on radiation response, and 
how we could target this hypoxic resistance by replacing oxygen by an oxygen mimicker 
in the radiobiological process. We also wanted to investigate the underlying cause of 
hypoxia, to maybe intervene at that stage and enhance radiation efficacy. In the introduction, 
we already discussed the multiple etiologies of hypoxia where the immature tumor vascular 
network plays an important role. In the last chapter (6) we focused on this tumor 
angiogenesis as cause of hypoxia and performed an integrated study on the effect of 
irradiation and antiangiogenic therapy on tumor vasculature, tumor microenvironment (e.g. 
hypoxia) and tumor growth in a xenograft colorectal cancer mouse model. This model was 
 
118 
chosen because anti-angiogenic agents have already proven their benefits in metastatic 
colorectal cancer patients. On the one hand, we investigated the hypoxia status of 
subcutaneous xenografts with an OxyLite probe and immunohistochemistry (exogenous 
marker pimonidazole) and on the other hand, the underlying vascular changes were 
investigated with in vivo fluorescence microscopy in dorsal skinfold window chambers 
(DSWC), with DCE-MRI of subcutaneous xenografts and with immunohistochemisty 
(endoglin) of xenografts. We aimed to link the vascular changes of IVM (DSWC tumor 
model) with changes in DCE-MRI parameters (subcutaneous tumor model), so in the future, 
DCE-MRI might be used to analyze the vascular status of tumors. Our results showed that 
all tumors were highly hypoxic before treatment as was measured with OxyLite probes. 
Despite this hypoxia, radiotherapy managed to inhibit tumor growth control partially, but 
as expected, cediranib further increased radiation induced growth control. We showed that 
after cediranib treatment (pan-VEGFR-inhibitor), a window of normalization arises where 
vessels are less tortuous, less permeable and less dilated and where hypoxia is decreased. If 
radiotherapy is applied during the normalization period, as in our study, cediranib acts as a 
radiosensitizer and leads to increased tumor control. Unfortunately, we could not link the 
observed vascular changes of in vivo fluorescence microscopy with parameters calculated 
from DCE-MRI that was performed 3 days after cessation of cediranib administration, 
because VEGF-stimulated tumor angiogenesis had probably relapsed at that time point. 
 
We would like to also indicate limitations of this thesis.  
First, the use of two tumor types could be seen as a limiting factor. Our first focus was 
esophageal cancer, as there is an existing clinical need for predictive biomarkers and patient 
stratification. To investigate tumor angiogenesis as underlying mechanism, we opted for a 
CRC tumor model, because evidence exists for cediranib efficacy in colorectal cancer 
(metastatic setting). This difference in tumor types causes a certain incoherence between 
the two research questions, but it does not limit possible translation to the clinic, for 18F-
FAZA PET/CT and nimorazole in locally advanced esophageal and for cediranib in locally 
advanced rectal cancer.  
Second, a variety of techniques were used across the different experiments. In chapter 5, 
18F-FAZA PET/CT and IHC with pimonidazole were used, while in chapter 6, OxyLite 
probe, DCE-MRI, in-vivo microscopy, IHC pimonidazole/Hoechst and Samba Preclin 
probe. It would have been interesting to integrate these techniques in one project, to validate 
 
119 
measurements and make stronger conclusions on cause-effect. For example, including 18F-
FAZA PET/CT in chapter 6 could maybe select tumors that would benefit from cediranib 
treatment and would provide an added value to the experiments. 
As last, no clinical data were included, limiting conclusions to the preclinical setting. 
Predictions about possible clinical applicability and future clinical studies are described in 
the next chapter. 
 
In conclusion, this thesis emphasized the importance of tumor hypoxia as predictive 
biomarker and target for treatment. For the first time, it was shown that 18F-FAZA PET/CT 
can predict radiation response with high sensitivity and specificity in an EAC mouse model, 
and that repeated imaging contributes to the evaluation of treatment-induced changes in 
hypoxia. We further showed that hypoxia-induced radioresistance can be decreased by 
replacement of oxygen in the radiochemical process with nimorazole. As last, tumor 
angiogenesis was investigated as underlying mechanism of hypoxia. We supported its 
importance and showed that cediranib (pan-VEGFR inhibitor) increases radiation efficacy 
through a transient normalization of tumor vessels and subsequent decrease of hypoxia in a 






























CHAPTER 8: GENERAL RELEVANCE AND FUTURE 
PERSPECTIVES 
Cancer remains one of the most important causes of death worldwide [1]. Treatment mostly 
consists of a combination of chemotherapy, radiotherapy and/or surgery and is based on the 
TNM classification (UICC) of the tumor. This classification is determined by the size and 
extent of the primary tumor, number of nearby lymph nodes and whether the cancer has 
metastasized. However, it has been observed that tumors with the same TNM stage and 
treated with the same therapy, can have a completely different response to treatment. This 
suggests that tumors are more diverse than the factors described by the TNM stage. Indeed, 
tumors differ strongly from one another with respect to genetics, epigenetics and 
microenvironmental characteristics. In the future, it will be critical to include these 
individual tumor characteristics in cancer staging and treatment, to offer a more tumor and 
patient-specific approach. 
 
In an era where medicine is evolving to a more patient-tailored and individualized approach, 
biomarkers are highly important. The world health organization defines them as ‘any 
substance, structure or process that can be measured in the body or its products and 
influence or predict the incidence of outcome or disease’. The most known and widespread 
biomarker is Her2/neu (human epidermal growth factor receptor 2) and is a good example 
of how biomarkers can influence clinical decision making and improve patient’s outcomes. 
Her2/neu is overexpressed in different tumor types (breast cancer, gastric cancer) and has 
been correlated with worse prognosis [166, 167].  The discovery of the targeted agent 
trastuzumab (Herceptin), a monoclonal antibody to the Her2-receptor, brought change to 
his. Trastuzumab showed to increase overall survival of patients with Her2/neu 
overexpressed breast cancers and is now used in the daily work-up of breast cancer patients 
[168]. 
 
This thesis is part of the quest for biomarkers to offer cancer patients a more tumor specific 
and individualized therapy. We focused on tumor hypoxia for several reasons. First, it is a 
microenvironmental characteristic that is present in almost all solid tumors so the potential 
applicability is wide. Second, preclinical as well as clinical evidence exists that tumor 
hypoxia is correlated with worse outcomes in different solid tumors. Third, tumor hypoxia 
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can be measured through non-invasive techniques, which is attractive for the translation to 
patients. Fourth, numerous targeting methods have been described, for example hypoxia 
activated prodrugs or intensity modulated radiotherapy (IMRT), which ensures the potential 
influence on daily clinical decision making. 
 
This thesis showed that 18F-FAZA PET/CT predicts radiation response in an EAC tumor 
model, which suggests that 18F-FAZA PET/CT could play a role in predicting treatment 
response of EAC patients. This could have several advantages.  
First, outcomes of esophageal cancer patients could be improved. Esophageal cancer 
remains a difficult disease to treat. Treatment has evolved from a surgical approach only, 
to a more multimodal therapy with chemo- and radiotherapy. The MAGIC and recent 
CROSS trial have confirmed that addition of neoadjuvant treatment is superior to surgery 
alone in patients with locally advanced disease [82, 169]. Further, two biological agents 
have been FDA-approved. Trastuzumab, targeting Her2/neu, and ramucirumab, targeting 
VEGFR2, showed to improve overall survival in randomized phase III trials in unresectable 
or metastatic gastro-esophageal junction tumors (ToGa trial [170], REGARD and 
RAINBOW trial [171, 172]). However, about 70% of esophageal cancer patients show 
residual disease after neoadjuvant chemoradiation [116]. If these partial responders could 
be identified with 18F-FAZA PET/CT before treatment, their outcomes could be improved 
by methods of hypoxia targeting (e.g. nimorazole or IMRT).  
Second, 18F-FAZA PET/CT is a non-invasive technique that has already been used in 
patients in clinical trials [161, 163, 173]. Besides the exposure to irradiation, 18F-FAZA 
PET/CT seems to have no major disadvantages for the patient.  
Third, the imaging can be performed on a standard PET/CT scanner that is routinely used 
for 18F-FDG PET/CT imaging. If the radionuclide department of the hospital has the 
permission to produce 18F-FAZA, all technical necessities are available to start a trial. 
 
Future work of our team will include a clinical study where 18F-FAZA PET/CT will be 
introduced for locally advanced esophageal adenocarcinoma patients requiring nCRT. First, 
a pilot study should be performed to determine a clinical cut-off of FAZA-tumor uptake 
that is predictive for therapy response. Patients need to be divided in responder and non-
responders which can be done based on the pathological characteristics of the resection 
specimen (e.g. Mandard regression score). If a correlation between pretreatment 18F-FAZA 
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uptake and treatment response can be confirmed, treatment modifications can be considered 
to improve patient outcomes.  
If a modifier like nimorazole would be used, it seems useful to repeat 18F-FAZA PET/CT 
during neoadjuvant treatment to reassess hypoxia status of tumors. As was seen in our study, 
most of the tumors reoxygenated upon treatment. If reoxygenation is found, the modifier 
might be discontinued.  
Also for dose-painting, repeating the 18F-FAZA PET/CT scan is important because the 
hypoxia distribution changes over time, so the irradiation mapping at the beginning of 
treatment will not be useful during the full treatment. Whether an 18F-FAZA PET/CT after 
ending nCRT, so before surgery, would be interesting is arguable. We found no evidence 
that reoxygenation of tumors is linked to treatment response in our model. Further, 18F-FDG 
PET is known to be correlated with treatment response, so it would be more useful to 
perform an 18F-FDG PET.  
Additionally, patient survival data and relapse data will be monitored to also correlate 
pretreatment 18F-FAZA PET/CT with prognosis. Later, this could be extended to other 
tumor types (e.g. rectal cancer, lung cancer…). 
 
Further, this thesis showed how anti-angiogenic therapy with cediranib normalizes tumor 
vasculature, reduces tumor hypoxia and enhances radiotherapy efficacy in a CRC tumor 
model. This stresses the importance of hypoxia in CRC and the potential role of cediranib 
in addition to radiotherapy. At present, patients with locally advanced rectal cancer are 
treated with neoadjuvant chemoradiation followed by surgery [174]. Addition of targeted 
agents such as bevacizumab (targeting VEGF-A) or cetuximab (targeting EGFR) have been 
examined, but provided conflicting results [154, 155, 175]. Whether cediranib will improve 
patients’ outcomes in the neoadjuvant setting, with acceptable toxicities, is to be 
investigated. 
 
In conclusion, tumor hypoxia is a long-known problem within oncology with little impact 
in the daily clinic. This is partially because hypoxia detection methods have not reached the 
routine clinical work-up of cancer patients. To continue enhancing patients’ outcomes and 
minimizing useless treatments, we are convinced a patient-tailored approach is required 































CHAPTER 9: SUMMARY 
In a time of continuous development of new approaches in cancer treatment, combined with 
the heterogeneous aspects of tumors, the search for biomarkers to predict treatment response 
and prognosis is extensive. Tumor hypoxia as a biomarker, is a very interesting research 
area, because it has been proven to be a negative predictive and prognostic marker in certain 
solid tumors. After decades of research to target hypoxia, little have reached the clinical 
setting. Mostly because no patient identification was performed and as such, they failed to 
improve outcomes. In this thesis, we present an integrated study on hypoxia in solid tumors 
and investigate its role as biomarker and target for individualized therapy.  
 
The first part of this thesis (chapter 3-5) focused on esophageal adenocarcinoma, an 
aggressive disease with poor survival rates and unpredictable response to neoadjuvant 
therapy. Our aim was to investigate the predictive value of 18F-FAZA PET/CT, a non-
invasive hypoxia imaging method, to radiation response in an EAC tumor model and to 
study the radiosensitizing effect of nimorazole, a promising hypoxia targeting molecule.  
We first described the development of an orthotopic and subcutaneous EAC xenograft 
model in nude mice in chapter 3. Two different human EAC cell lines were used to induce 
xenografts. The first, OE33, is derived from a stage IIA adenocarcinoma of the lower 
esophagus with poor differentiation. The second was OACM5 1.C and is derived from a 
metastatic lymph node of a distal esophageal adenocarcinoma. After injection of the cell 
lines at an orthotopic and ectopic (subcutaneous) site, in vivo tumor growth was evaluated. 
Additionally, functional cell line characteristics were examined through in vitro assays for 
collagen invasion, cell-cell adherence and clonogenicity. OE33 was found to induce 
orthotopic and subcutaneous small, slow growing tumors and was thus not ideal to 
investigate the predictive value of 18F-FAZA PET/CT for radiation response. The second 
cell line, OACM5 1.C had no tumor take orthotopically and only 50% tumor take 
subcutaneously. However, through in vivo selection, a daughter cell line of OACM5 1.C 
was developed, named OACM5 1.C SC1, with enhanced tumor take rates, and most 
importantly, leading to larger and faster growing tumors that could be used to study 
radiation response and predictive value of 18F-FAZA PET/CT. 
Subsequently, the feasibility of 18F-FAZA PET/CT in both the orthotopic and subcutaneous 
EAC tumor model was tested and described in chapter 4.  A problem of intense background 
activity in the gastro-intestinal tract was encountered due to metabolization of the tracer. 
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Because of this, orthotopic tumors could not be delineated. This is an unavoidable aspect of 
nitroimidazole hypoxia tracers, but will probably not cause such a problem in patients 
because of larger structures and better soft tissue resolution on CT. Therefore, we decided 
to continue with the subcutaneous model in which 18F-FAZA PET/CT enabled clear 
visualization of tumor hypoxia distribution and hypoxia quantification. 
In chapter 5, we evaluated the predictive value of 18F-FAZA PET/CT for radiation response 
in subcutaneous EAC xenografts and found that a tumor-to-background ratio of 3.59 or 
higher could identify tumors that responded worse to radiotherapy. We then examined 
whether nimorazole, a hypoxic radiosensitizer, could increase radiotherapy efficacy in 
hypoxic conditions. Nimorazole significantly increased in vitro radiotherapy efficacy in 
hypoxic conditions. In the EAC xenografts, a trend was seen to better inhibition of tumor 
cell proliferation, but results on tumor growth control were limited. FAZA uptake after 
treatment was also evaluated, but no link was found between treatment response and 
normalization of hypoxia status. We did see a reoxygenation in almost all tumors after 
treatment. These results suggest that 18F-FAZA PET/CT could play an important role in 
predicting treatment response in EAC patients and that nimorazole might decrease hypoxia 
induced radioresistance. 
 
In the second section of this thesis, the focus was shifted to tumor angiogenesis as one of 
the underlying mechanisms of tumor hypoxia, and was described in chapter 6. This chapter 
focused on colorectal cancer, one of the most common tumor types worldwide. An 
integrated study on tumor vasculature and microenvironment (e.g. hypoxia) was performed, 
in response to radiotherapy and anti-angiogenic therapy. CRC xenografts were induced in 
dorsal skinfold window chambers and subcutaneously in the hind legs of nude mice. In vivo 
fluorescence microscopy of the DSWC was performed and immunohistochemistry, pO2 and 
IFP measurements and DCE-MRI were performed in the subcutaneous xenografts. The pan-
VEGFR inhibitor cediranib was investigated as anti-angiogenic drug. We showed that all 
tumors expressed a significant amount of tumor hypoxia and that cediranib normalized 
tumor vasculature and decreased tumor hypoxia, leading to an enhanced effect of 
radiotherapy.  
 
In conclusion, this thesis emphasizes the importance of tumor hypoxia in solid tumors. 
Hypoxia imaging with 18F-FAZA PET/CT is a useful detection and quantification method 
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and is predictive for radiation response in an EAC xenograft model. Further we showed that 
targeting hypoxia, by nimorazole and by cediranib, increases radiation response, which 







In een tijd waar de ontwikkelingen binnen de oncologie niet stilstaan, gecombineerd met de 
grote heterogeniteit van tumoren, is de zoektocht naar biomerkers om therapierespons en 
prognose te voorspellen enorm. In bepaalde solide tumoren werd reeds aangetoond dat 
tumorhypoxie gecorreleerd is met een slechtere therapierespons en prognose. 
Tumorhypoxie zou dus een zeer interessante biomerker kunnen zijn en vormt een belangrijk 
onderzoeksdomein in de oncologie. Na tientallen jaren onderzoek naar mogelijkheden om 
tumorhypoxie aan te pakken, zijn er slecht weinig geïmplementeerd in de kliniek. Er werd 
meestal geen identificatie verricht van hypoxische versus niet-hypoxische tumoren, 
waardoor de therapieën gericht op hypoxie, er niet in slaagden de outcomes te verbeteren. 
Deze thesis is een geïntegreerde studie over hypoxie in solide tumoren, waar hypoxie wordt 
onderzocht als mogelijke biomerker en als doelwit voor geïndividualiseerde behandeling.  
 
Het eerste deel van deze thesis (hoofdstuk 3-5) richtte zich op slokdarmkanker van het type 
adenocarcinoom. Deze agressieve ziekte heeft slechte overlevingscijfers en reageert 
onvoorspelbaar op neoadjuvante therapie. Ons doel was om de voorspellende waarde van 
18F-FAZA PET/CT, een niet-invasieve manier om hypoxie te beeldvormen, voor respons 
op radiotherapie te onderzoeken in een preklinische studie en om het radiosensitizerend 
effect van nimorazole, een veelbelovende therapie gericht op hypoxie, te bestuderen. 
We zijn gestart met het beschrijven van de ontwikkeling van een orthotoop en subcutaan 
slokdarm adenocarcinoom model in naakte muizen (hoofdstuk 3). Hierbij werden 2 
verschillende humane cellijnen gebruikt om xenografts te induceren. De eerste, OE33, stamt 
af van een stadium IIA adenocarcinoom van de distale slokdarm, met slechte differentiatie. 
De tweede, OACM5 1.C stamt af van een metastatische lymfeknoop van een 
adenocarcinoom van de distale slokdarm. Na injectie van de cellen op een orthotope (distale 
slokdarm) of ectopische (subcutaan in de dijen) plaats werd in vivo tumorgroei geëvalueerd. 
Verder werden met verschillende in vitro testen functionele eigenschappen van de cellen 
onderzocht met betrekking op cel-cel adherentie, invasiviteit en clonogeniciteit. OE33 
leidde tot de ontwikkeling van kleine, traag groeiende tumoren, zowel orthotoop als 
ectopisch, en was dus niet geschikt om de voorspellende waarde van 18F FAZA PET/CT 
voor respons op radiotherapie te onderzoeken. Met de tweede cellijn, OACM5 1.C, konden 
geen orthotope tumoren ontwikkeld worden, en leidde slechts 50% van de subcutane 
injecties tot ontwikkeling van tumoren. Echter, we slaagden erin om met een in vivo selectie 
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techniek een dochtercellijn te ontwikkelen, OACM5 1.C SC1, die tot procentueel meer 
tumorontwikkeling leidde en belangrijker, resulteerde in grotere en sneller groeiende 
tumoren. Deze in vivo geselecteerde cellijn kan in een toekomstige studie gebruikt worden 
om de voorspellende waarde van 18F FAZA PET/CT voor respons op radiotherapie te 
onderzoeken. 
Vervolgens werd de uitvoerbaarheid van 18F-FAZA PET/CT beeldvorming in beide tumor 
modellen (orthotoop en subcutaan) onderzocht en beschreven in hoofdstuk 4. Daar botsten 
we op een probleem van intense achtergrondactiviteit van de tracer ter hoogte van de lever 
en het maagdarmstelsel, door afbraak en excretie van de tracer aldaar. Hierdoor konden de 
tumoren in de distale slokdarm niet gevisualiseerd en afgelijnd worden op de PET/CT scan. 
Dit is een onvermijdbaar aspect van nitroimidazole tracers, maar zal bij patiënten 
waarschijnlijk niet zo’n probleem vormen gezien de structuren groter zijn en de CT resolutie 
voor zachte weefsels beter is. Daarom besloten we verder te gaan met het subcutane model, 
waar de distributie van tumorhypoxie duidelijk gevisualiseerd en afgelijnd kond worden 
met 18F-FAZA PET/CT. 
In hoofdstuk 5 evalueerden we de voorspellende waarde van 18F-FAZA PET/CT voor 
respons op radiotherapie in subcutane slokdarmadenocarcinoma xenografts. We toonden 
aan dat een tumor-to-background ratio van 3.59, met goede sensitiviteit en specificiteit, 
tumoren kon identificeren die slechter zouden reageren op radiotherapie. Daarnaast 
onderzochten we of nimorazole, een radiosensitiseerder gericht op hypoxie, het effect van 
radiotherapie in hypoxische omstandigheden kon verbeteren. Nimorazole verbeterde 
significant het effect van radiotherapie in hypoxische omstandigheden in de in vitro setting, 
en er werd een trend gezien in de xenografts tot betere inhibitie van kankercel proliferatie. 
Het effect op tumorgroei was eerder beperkt. We evalueerde ook 18F-FAZA-opname na 
therapie, maar vonden geen correlatie tussen therapierespons en normalisatie van de 
hypoxie status. Wel zagen we een reoxygenatie in bijna alle tumoren na therapie. Deze 
resultaten tonen aan dat 18F-FAZA PET/CT een belangrijke rol zou kunnen spelen in het 
voorspellen van therapierespons in slokdarmadenocarcinoma patiënten en dat nimorazole 
de hypoxie geïnduceerde radioresistentie zou kunnen verminderen.  
 
Het tweede deel van de thesis richtte zich op tumor angiogenese als onderliggende oorzaak 
van tumorhypoxie (hoofdstuk 6). Hiervoor richtten we ons op colorectaal kanker, een van 
de meest voorkomende kankers wereldwijd, waarvoor reeds bewezen is dat angiogenese 
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remmende therapie een effect heeft bovenop de bestaande modaliteiten. Een geïntegreerde 
studie over de structuur en functie van tumorale bloedvaten, en de tumor micro-omgeving 
(waaronder hypoxie), werd verricht. Het effect van radiotherapie en anti-angiogene 
behandeling met de pan-VEGR inhibitor cediranib werd onderzocht. Hiervoor gebruikten 
we colorectale xenografts in dorsal skinfold window chambers en subcutaan in de dijen, in 
naakte muizen. In vivo fluorescentie microscopie van de DSWC werd verricht en 
immunohistochemische kleuringen, pO2 en IFP probe metingen en DCE-MRI werden 
verricht van de subcutane xenografts. We toonden aan dat alle tumoren een aanzienlijke 
hoeveelheid tumorhypoxie bezaten en dat cediranib de tumorale vaten normaliseerde, 
tumorhypoxie verminderde en het effect van radiotherapie verbeterde.  
 
Deze thesis benadrukt het belang van tumorhypoxie in solide tumoren. We besluiten dat 
18F-FAZA PET/CT een bruikbare techniek is om hypoxie te meten en dat het de respons op 
radiotherapie in een slokdarmadenocarcinoma xenograft model kan voorspellen. Verder 
toonden we aan dat hypoxiegerichte therapie, met nimorazole en cediranib, de respons op 
radiotherapie verbetert, wat de toepasbaarheid van hypoxie als biomerker en doelwit van 
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